PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 1Title Page
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-
CONTROLLED, CROSSOVER, FIRST-IN-HUMAN STUDY TO ASSESS THE 
SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE 
ASCENDING ORAL DOSES OF PF-06954522 IN HEALTHY ADULT 
PARTICIPANTS
Study Intervention Number: PF-06954522
Study Intervention Name: [CONTACT_336280]: [ADDRESS_415339]/EU CT Number: NA
ClinicalTrials.gov ID:  NA
Pediatric Investigational Plan Number: NA
Protocol Number: C4001001
Phase: 1
Sponsor Legal Address: [COMPANY_007] Inc.
[ADDRESS_415340] East[LOCATION_001], NY [ZIP_CODE]
Brief Title: A Study to Learn How Different Amounts of the Study Medicine called 
PF-[ADDRESS_415341] in the Body in Healthy Adults
This document and accompanying materials contain confidential information belonging to [COMPANY_007]. Except as 
otherwise agreed to in writing, by [CONTACT_22788], you agree to hold this information in confidence and not copy or disclose it to others (except where required by [CONTACT_1289]) or use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, [COMPANY_007] 
must be promptly notified.
090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 2Document History
Document Version Date
Original protocol 17 Jul y2023090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 3TABLE OF CONTENTS
LIST OF TABLES................................................................................................................. ....[ADDRESS_415342] OF FIGURES ................................................................................................................ ...8
1. PROTOCOL  SUMMARY.....................................................................................................9
1.1. Synopsis .................................................................................................................. ..9
1.2. Schema .................................................................................................................... 14
1.3. Schedule of Activities .............................................................................................16
2. INTRODUCTION ...............................................................................................................2 1
2.1. Study R ationale .......................................................................................................21
2.2. Background .............................................................................................................21
2.2.1. Nonclinical Pharmacology..........................................................................222.2.2. Nonclinical Pharmacokinetics and Metabolism .........................................222.2.3. Biopharmaceutics .......................................................................................232.2.4. Nonclinical Safety ......................................................................................23
2.3. Benefit/Risk Assessment.........................................................................................24
2.3.1. Risk Assessment .........................................................................................262.3.2. Benefit Assessment.....................................................................................282.3.3. Overall Benefit/Risk Conclusion................................................................28
3. OBJECTIVES AND ENDPOINTS .....................................................................................284. STUDY DESIGN................................................................................................................ .28
4.1. Overall Design.........................................................................................................284.2. Scientific Rationale for Study Design.....................................................................30
4.2.1. Choice of Contraception/Barrier Requirements .........................................31
4.3. Justification for Dose ..............................................................................................31
4.3.1. Human PK Prediction.................................................................................314.3.2. Predicted Human Efficacious Dose and Concentration..............................324.3.3. Human Exposure Stoppi[INVESTIGATOR_336241]..............................................................324.3.4. Rationale for Dose Selection ......................................................................32
4.4. End of Study Definition ..........................................................................................34
5. STUDY POPULATION ......................................................................................................34
5.1. Inclusion Criteria.....................................................................................................34
5.2. Exclusion Criteria....................................................................................................35090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 45.3. Lifestyle Cons iderations..........................................................................................37
5.3.1. Contraception..............................................................................................375.3.2. Meals and Dietar y Restrictions...................................................................38
5.3.3. Caffeine, Alcohol, and Tobacco .................................................................395.3.4. Activity .......................................................................................................39
5.4. Screen Failures ........................................................................................................40
6. STUDY INTERVENTION(S) AND CONCOMITANT THERAPY .................................40
6.1. Study Intervention(s) Administered ........................................................................40
6.1.1. Administration ............................................................................................41
6.2. Preparation, Handling, Storage, and Accountability...............................................42
6.2.1. Preparation and Dispensing ........................................................................43
6.3. Assignment to Study Intervention...........................................................................436.4. Blinding.................................................................................................................. .43
6.4.1. Blinding of Participants ..............................................................................436.4.2. Blinding of Site Personnel..........................................................................446.4.3. Blinding of the Sponsor..............................................................................446.4.4. Sensitive Clinical Data ...............................................................................446.4.5. Breaking the Blind......................................................................................44
6.5. Study Intervention Compliance...............................................................................456.6. Dose Modification...................................................................................................45
6.6.1. Dose Escalation and Stoppi[INVESTIGATOR_1869] ..........................................................46
6.7. Continued Access to Study Intervention After the End of the Study......................476.8. Treatment of Overdose............................................................................................476.9. Prior and Concomitant Therapy ..............................................................................47
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/ WITHDRAWAL...........................................................................48
7.1. Discontinuation of Study Intervention ....................................................................48
7.1.1. Potential Cases of Acute Kidney Injury .....................................................487.1.2. Liver Injury.................................................................................................50
7.1.3. ECG Changes..............................................................................................507.1.4. COVID-19 ..................................................................................................50
7.2. Participant Discontinuation/Withdrawal From the Study .......................................51090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 57.2.1. Withdrawal of Consent...............................................................................[ADDRESS_415343] to Follow-Up ...................................................................................................52
8. STUDY ASSESSMENTS AND PROCEDURES...............................................................52
8.1. Administrative and Baseline Procedures.................................................................528.2. Efficacy Assessments..............................................................................................538.3. Safety Assessments .................................................................................................53
8.3.1. Physical Examinations................................................................................548.3.2. Vital Signs ..................................................................................................54
[IP_ADDRESS]. Blood Pressure and Pulse Rate..................................................[IP_ADDRESS]. Respi[INVESTIGATOR_13581]........................................................................[IP_ADDRESS]. Body Temperature.....................................................................55
8.3.3. Electrocardiograms.....................................................................................55
[IP_ADDRESS]. Continuous Cardiac Monitoring by [CONTACT_336258] .........................56
8.3.4. Clinical Safety La boratory Asse ssments ....................................................56
8.4. Adverse Events, Serious Adverse Events, and Other Safety Reporting .................57
8.4.1. Time Period and Frequency for Collecting AE and SAE Information.......57
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety...............................................[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF...................58
8.4.2. Method of Detecting AEs and SAEs ..........................................................588.4.3. Follow-up of AEs and SAEs.......................................................................598.4.4. Regulatory Reporting Requirements for SAEs...........................................598.4.5. Environmental Exposure, Exposure During Pregnancy or 
Breastfeeding, and Occupational Exposure .....................................................59
[IP_ADDRESS]. Exposure During Pregnancy......................................................[IP_ADDRESS]. Exposure During Breastfeeding ................................................[IP_ADDRESS]. Occupational Exposure .............................................................62
8.4.6. Cardiovascular and Death Events...............................................................628.4.7. Disease-Related Events and/or Disease-Related Outcomes Not 
Qualifying as AEs or SAEs..............................................................................[ADDRESS_415344].............................................................62
[IP_ADDRESS]. Lack of Efficacy........................................................................62
8.4.9. Medical Device Deficiencies......................................................................62
8.4.10. Medication Errors .....................................................................................62090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
P F -0 6 9 5 4 5 2 2 
Pr ot oc ol C4 0 0 1 0 0 1 
Fi nal Pr ot oc ol, 1 7 J ul y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol T e m plate ( 1 4 A pril 2 0 2 3) 
Pa ge 68. 5. P har mac o ki netics ................................ ................................ .................................... 6 3 
8. 6. Ge netics ................................ ................................ ................................................... 6 4 
8. 6. 1. S pecifie d Ge netics ................................ ...................................................... 6 4 
8. 6. 2. Retai ne d Researc h Sa m ples f or Ge netics ................................................... 6 4 
8. 7. Bi o mar kers ................................ ................................ .............................................. 6 4 
8. 7. 1. Plas ma f or Meas ure me nt of ............................................................... 6 4 
8. 7. 2. Retai ne d Researc h Sa m ples f or Bi o mar kers ............................................... 6 5 
8. 8. I m m u n o ge nicit y Assess me nts ................................ ................................................. 6 6 
8. 9. Healt h Ec o n o m ics ................................ ................................ ................................... 6 6 
9. S T A TI S TI C A L C O N SI D E R A TI O N S ................................ ................................................ 6 6 
9. 1. Statistical H y p ot hesis ................................ .............................................................. 6 6 
9. 2. A nal y sis Sets ................................ ................................ ........................................... 6 6 
9. 3. Statistical A nal y ses ................................ ................................ ................................. 6 7 
9. 3. 1. Safet y A nal ys es ................................ .......................................................... 6 7 
9. 3. 1. 1. Electr ocar di o gra m A nal y ses ...................................................... 6 7 
9. 3. 2. P K A nal y sis ................................ ................................ ................................ 6 8 
9. 3. 2. 1. Deri vati o n of P F -0 6 9 5 4 5 2 2 P K Para meters .............................. 6 8 
9. 3. 2. 2. Statistical Met h o ds f or P K Data ................................................ 6 9 
9. 3. 3. Tertiar y / E x pl orat or y  E n d p oi nt(s) A nal ys is ................................................ 6 9 
9. 3. 4. Ot her A nal ys es ................................ ............................................................ 6 9 
9. 4. Interi m A nal ys es ................................ ................................ ..................................... 7 0 
9. 5. Sa m ple Size Deter mi nati o n ................................ ..................................................... 7 0 
1 0. S U P P O R TI N G D O C U M E N T A TI O N A N D O P E R A TI O N A L 
C O N SI D E R A TI O N S ................................ ................................ .......................................... 7 1 
1 0. 1. A p pe n di x 1: Re g ulat or y , Et hical, a n d St u d y  O versi g ht C o nsi derati o ns ............... [ADDRESS_415345] ure ................................ ............................................... 7 3 0 9 0 1 7 7 e 1 9 e 0f 3 af c\ A p pr o v e d\ A p pr o v e d O n: 1 9- J ul- 2 0 2 3 0 1: 5 5 ( G M T) C CI 
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page [IP_ADDRESS]. Data Monitoring Committee ...................................................73
10.1.6. Dissemination of Clinical Study Data ......................................................7310.1.7. Data Qualit y Assurance ............................................................................75
10.1.8. Source Documents....................................................................................7610.1.9. Use of Medical Records............................................................................7610.1.10. Study and Site Start and Closure ............................................................7710.1.11. Publication Policy...................................................................................7710.1.12. Sponsor’s Medically Qualified Individual..............................................78
10.2. Appendix 2: Clinical Laboratory Tests .................................................................7910.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-Up, and Reporting .....................................................................81
10.3.1. Definition of AE .......................................................................................8110.3.2. Definition of an SAE ................................................................................8210.3.3. Recording/Reporting and Follow-Up of AEs and/or SAEs During 
the Active Collection Period............................................................................83
10.3.4. Reporting of SAEs....................................................................................87
10.4. Appendix 4: Contraceptive and Barrier Guidance ................................................88
10.4.1. Male Participant Reproductive Inclusion Criteria ....................................8810.4.2. Female Participant Reproductive Inclusion Criteria.................................8810.4.3. Woman of Childbearing Potential ............................................................8910.4.4. Contraception Methods.............................................................................90
10.5. Appendix 5: Genetics ............................................................................................9210.6. Appendix 6: Liver Safety: Suggested Actions and Follow-Up Assessments .......9310.7. Appendix 7: Kidney Saf ety: Monitoring Guidelines ............................................95
10.7.1. Laboratory Assessment of Change in Kidney Function and 
Detection of Kidney Injury ..............................................................................95
10.7.2. Age-Specific Kidney Function Calculation Recommendations...............95
[IP_ADDRESS]. Adults (18 Years and Above)—2021 CKD-EPI 
[INVESTIGATOR_185560] ...........................................................................................95
10.7.3. Kidney Function Calculation Tools..........................................................95
10.7.4. Adverse Event Grading for Kidney Safety Laboratory 
Abnormalities...................................................................................................96
10.8. Appendix 8: ECG Findings of Potential Clinical Concern ...................................97090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 810.9. Appendix 9: Prohibited Concomitant Medications That May Result in DDI.......99
10.10. Appendix 10: Abbreviations .............................................................................[ADDRESS_415346] OF TABLES
Table 1. Study Schedule of Assessments................................................................16Table 2. Study Schedule of Assessments for PK, Vitals, and ECGs on Day 1 
of Each Period...........................................................................................20
Table 3. Predicted Human Exposure and Safety Margins Following 
Administration of Single Oral Doses of PF-06954522.............................33
Table 4. Plasma PF-06954522 PK Parameters .......................................................68Table 5. Protocol -Required Laboratory Assessments............................................79Table 6. Protocol-Required Laboratory Assessments – Reflex Testing.................[ADDRESS_415347] OF FIGURES
Figure 1. Study Design Schematic: Sequential, Placebo-Controlled, 5-Period, 
Crossover Design......................................................................................15090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 91. PROTOCOL SUMMARY 
1.1. Synopsis Protocol Title: 
A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, Crossover,
First-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of PF-06954522 in Healthy Adult Participants
Brief Title:A Study to Learn How Different Amounts of the Study Medicine Called PF-[ADDRESS_415348] in the Body in Healthy Adults
Regulatory Agency Identification Number(s):
US IND Number: [ADDRESS_415349]/EU CT Number: NA
ClinicalTrials.gov ID:  NA
Pediatric Investigational Plan Number: NA
Protocol Number: C4001001
Phase: 1
Rationale:
PF-06954522 is an orally administered small molecule glucagon-like peptide-1 receptor 
(GLP-1R) agonist that is being developed as an adjunct to diet and exercise for the treatment of type 2 diabetes mellitus (T2DM). The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of single ascending oral doses of PF-[ADDRESS_415350] time that PF-06954522 is administered to humans. The safety, tolerability, and PK results obtained from this study will inform future clinical development of PF-06954522.090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 10Objectives and Endpoints:
Objectives Endpoints
Primary: Primary: 
!To evaluate the safety and tolerability of single 
oral doses of PF-06954522 administered to healthy adult participants.!Assessment of AEs, safety laboratory tests, vital 
signs (blood pressure, pulse rate, respi[INVESTIGATOR_336242]), cardiac telemetry and standard 12-lead ECGs, and PE.
Secondary: Secondary: 
!To characterize the plasma PK of PF-06954522 
following single oral doses of PF-06954522 
administered to healthy adult participants.!PF-06954522 PK parameters: AUC last, Cmax, Tmax, 
and if data permit AUC infand t ½.
Abbreviations: AE = adverse event; AUC inf= area under the plasma concentration-time curve from time 0 
extrapolated to infinite time; AUC last= area under the plasma concentration-time curve from time [ADDRESS_415351] quantifiable concentration; C max= maximum plasma concentration; 
ECG = electrocardiogram; PE = physical examination; PK = pharmacokinetic(s); t ½. = terminal half-life; 
Tmax= time for C max.
Overall Design: This study is a randomized, double-blinded (investigator- and 
participant-blinded), sponsor-open, first in human (FIH), single-ascending oral dose, 5-period crossover, placebo substitution design in 1 cohort of healthy adult participants. An optional cohort, enrolling healthy adult participants in up to 4 crossover periods, may be included to permit assessment of any of the following: repeat of a previously administered dose level; studying additional dose levels as dictated by [CONTACT_336259], tolerability, or PK of earlier dose levels; or any other assessment needed to meet the objectives of this study. A second optional cohort enrolling Japanese participants to receive PF-06954522 or placebo in up to 3 periods, may also be included.
Number of Participants: Approximately 24 healthy adult participants will be enrolled in the 
study. This includes up to approximately 10 healthy participants for Cohort 1, up to approximately 8 healthy participants for optional Cohort 2 and up to approximately 6 healthy Japanese participants for the optional Cohort 3. The actual number of Japanese participants may be adjusted based on emerging data or operational factors with a maximum sample size of up to 8 participants (6 receiving PF-06954522 and 2 receiving placebo in each period).
Note: "Enrolled" means a participant’s, or their legally authorized representative’s, 
agreement to participate in a clinical study following completion of the informed consent process and randomization to study intervention.090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
P F -0 6 9 5 4 5 2 2 
Pr ot oc ol C4 0 0 1 0 0 1 
Fi nal Pr ot oc ol, 1 7 J ul y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol T e m plate ( 1 4 A pril 2 0 2 3) 
Pa ge [ADDRESS_415352] u d y P o p ul ati o n :
K e y  i ncl usi o n a n d e xcl usi o n criteria are liste d bel o w: 
I ncl usi o n Criteri a 
Part ici pa nts m ust meet t he f oll o wi n g ke y  i ncl usi o n criteria t o be eli gi ble f or e nr oll me nt i nt o 
t he st u d y :
1. Male a n d fe male partici pa nts of n o n -c hil d beari n g p ote ntial a ge d [ADDRESS_415353] or y , p h y sical e xa mi nati o n, la b orat or y  tests, a n d car diac m o nit ori n g. 
2. B MI of 1 6 t o 3 0. 5 k g/ m 2; a n d a t otal b o d y wei g ht > 5 0 k g ( 1 1 0 l b) .
N ote : partici pa nts e nr olli n g as Ja pa nese m ust ha ve 4 bi ol o gical Ja pa nese gra n d pare nts w h o 
were b or n i n Ja pa n. A l o wer e ntr y wei g ht of 4 5 k g ma y  be c o nsi dere d if t he t otal bl o o d 
v ol u me c ollecti o n f or t h is c o h ort d oes N O T e xcee d 3 6 0 m L  o ver a n 8- wee k peri o d. 
E xcl usi o n Criteri a 
Partici pa nts wit h a n y  of t he f oll o wi n g c haracteristics/c o n diti o ns will be e xcl u de d: 
1. E vi de nce or hist or y  of cli nicall y  si g nifica nt he mat ol o gical, re nal, e n d ocri ne, p ul m o nar y , 
gastr oi ntesti nal, car di o vasc ular, he patic, ps y c hiatric, ne ur ol o gical, or aller gic disease 
(i ncl u di n g dr u g aller gies, b ut e xcl u di n g u ntreate d, as y m p t o matic, seas o nal aller gies at t he 
ti me of d osi n g). 
A n y  c o n diti o n p ossi bl y  affecti n g dr u g a bs or pti o n (e g, gastrect o m y , c h olec y stect o m y). 
Hist or y  of HI V i nfecti o n, he patitis B, or he patitis C; p ositi ve testi n g f or HI V, H Bs A g , 
H Bc A b, or H C V A b. Hist or y  of he patitis B vacci nati o n wit h a n is olate d p ositi ve 
H Bs A b res ult is all o we d. 
2. Pers o nal or fa mil y hist or y of me d ullar y  t h y r oi d carci n o ma ( M T C) or m ulti ple e n d ocri ne 
ne o plasia s y n dr o me t y pe 2 ( M E N 2), or partici pa nts wit h s us pecte d M T C per t he 
i n vesti gat or’s j u d ge me nt. 
3. A n y  me dical or ps yc hi atric c o n diti o n i ncl u di n g rece nt ( wit hi n t he past ye ar) or acti ve 
s uici dal i deati o n/ be ha vi or or la b orat or y  a b n or malit y  or ot her c o n diti o ns t hat ma y  i ncrease 
t he ris k of st u d y  partici pati o n or, i n t he i n vesti gat or’s j u d g me nt, ma ke t he partici pa nt 
i na p pr o priate f or t he st u d y . 
4. Use of prescri pti o n or n o n prescri pti o n dr u gs a n d dietar y  a n d her bal s u p ple me nts wit hi n 
7da y s or 5 half -li ves ( w hic he ver is l o n ger) pri or t o t he first d ose of st u d y  i nter ve nti o n, 
wit h t he e xce pti o n of  0 9 0 1 7 7 e 1 9 e 0f 3 af c\ A p pr o v e d\ A p pr o v e d O n: 1 9- J ul- 2 0 2 3 0 1: 5 5 ( G M T) C CI 
P F -0 6 9 5 4 5 2 2 
Pr ot oc ol C4 0 0 1 0 0 1 
Fi nal Pr ot oc ol, 1 7 J ul y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol T e m plate ( 1 4 A pril 2 0 2 3) 
Pa ge [ADDRESS_415354] ( dr u g or vacci ne) wit hi n 3 0 da y s 
( or as deter mi ne d b y t he l ocal re q uire me nt) or [ADDRESS_415355] u d y  ( w hic he ver is l o n ger). Partici pati o n i n st u dies of 
ot her i n vesti gati o nal pr o d ucts ( dr u g or vacci ne) at a n y  ti me d uri n g t heir partici pati o n i n 
t his st u d y .
6. A p ositi ve uri ne dr u g test at Scree ni n g or a d missi o n. 
7. Scree ni n g s u pi [INVESTIGATOR_190151] o o d press ure ( B P) ≥ 1 4 0 m m H g (s ys t olic) or ≥ 9 0 m m H g ( diast olic) 
f or partici pa nts < 6 0 years; a n d ≥ 1 5 0/ 9 0 m m/ H g f or partici pa nts ≥ [ADDRESS_415356]. If s ys t olic B P is ≥ 1 4 0 or 1 5 0 m m H g ( base d o n a ge) or 
diast olic ≥ 9 0 m m H g, t he B P s h o ul d be re peate d 2 m ore ti m es a n d t he a vera ge of t he 
3B P val ues s h o ul d be use d t o deter mi ne t he partici pa nt’s eli gi bilit y .
8. Re nal i m pair me nt as defi ne d b y a n esti mate d gl o mer ular filtrati o n rate (e G F R) of 
< 7 5 m L / mi n/ 1. 7 3 m². Base d u p o n partici pa nt a ge at scree ni n g, e G F R is calc ulate d usi n g 
t he rec o m me n de d Chr o nic Ki d ne y  D isease Epi [INVESTIGATOR_32450] o g y C olla b orati o n ( C K D -E PI) 
e q uati o ns t o deter mi ne eli gi bilit y (Screat -base d f or m ula ) a n d t o pr o vi de a baseli ne 
(Screat -S c y s c o m bi ne d f or m ula) t o q ua ntif y  s u bse q ue nt ki d ne y  safet y e ve nts. F or 
eli gi bil it y  assess me nt base d u p o n esti mate d re nal f u ncti o n, t he hi g her of t he scree ni n g 
a n d baseli ne e G F R val ues ma y  be use d. 
9. Sta n dar d [ADDRESS_415357] u d y  res ults (e g, Q Tc F > [ADDRESS_415358] i ve of m y ocar dial isc he mia, sec o n d- or t hir d -de gree atri o ve ntric ular ( A V) bl oc k, 
or seri o us bra d ya rr h yt h mias or tac h y arr h y t h mias). If Q Tc F e xcee ds 4 5 0 ms, or Q R S 
e xcee ds 1 2 0 ms, t he E C G s h o ul d be re peate d t wice a n d t he a vera ge of t he 3 Q Tc F or 
Q R S val ues use d t o deter mi ne t he partici pa nt’s eli gi bilit y . C o m p uter -i nter prete d E C Gs 
s h o ul d be o verrea d b y a p h ysicia n e x perie nce d i n rea di n g E C Gs bef ore e xcl u di n g a 
partici pa nt. 
[ADDRESS_415359], if dee me d necessar y: 
Ala ni ne a mi n otra nsferase (A L T ), as partate a mi n otra nsferase ( A S T ), or bilir u bi n 
≥1. 0 5 × u p per li mit of n or mal (U L N ). Partici pa nts wit h a n ele vate d t otal bilir u bi n 
c o nsiste nt wit h Gil bert’s Disease m a y ha ve a direct bilir u bi n meas ure d a n d w o ul d be 
eli gi ble f or t his st u d y  pr o vi de d t he direct bilir u bi n le vel is ≤ U L N;
T S H > U L N; 
H b A 1c ≥ 6. 5 %; 0 9 0 1 7 7 e 1 9 e 0f 3 af c\ A p pr o v e d\ A p pr o v e d O n: 1 9- J ul- 2 0 2 3 0 1: 5 5 ( G M T) C CI 
P F -0 6 9 5 4 5 2 2 
Pr ot oc ol C4 0 0 1 0 0 1 
Fi nal Pr ot oc ol, 1 7 J ul y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol T e m plate ( 1 4 A pril 2 0 2 3) 
Pa ge 1 3 He mat uria as defi ne d b y ≥1 + he me o n uri ne d i pstic k ;
Al b u mi n uria as defi ne d b y uri ne al b u mi n/creati n i n e rati o ( U A C R) > 3 0 m g/ g. 
[ADDRESS_415360] or y  of alc o h ol a b use or bi n ge dri n ki n g a n d/ or a n y  ot her illicit dr u g use or de pe n de nce 
wit hi n 6 m o nt hs of scree ni n g. Bi n ge dri n ki n g is defi ne d as a patter n of 5 ( male) a n d 
4 (fe male) or m ore alc o h olic dri n ks i n a b o ut 2 h o urs. As a ge neral r ule, alc o h ol i nta ke 
s h o ul d n ot e xcee d 1 4 u nits per wee k ( 1 u nit = 8 o u nces ( 2 4 0 m L ) beer, 1 o u nce ( 3 0 m L ) 
of 4 0 % s pi[INVESTIGATOR_17040], or 3 o u nces ( 9 0 m L ) of wi ne). 
1 2. Use of t o bacc o or nic oti ne- c o ntai ni n g pr o d ucts i n e xcess of t he e q ui vale nt of 
5ci garettes/ da y  or 2 c he ws of t o bacc o/ da y .
[ADDRESS_415361] u d y Ar ms a n d D ur ati o n: T he t otal d urati o n of partici pati o n fr o m t he scree ni n g visit t o t he 
tele p h o ne f oll o w -u p c o ntact will be a p pr o xi matel y [ADDRESS_415362] u d y I nter ve nti o n(s) 
I nter ve nti o n N a me P F -[ADDRESS_415363] b o 
I M P or NI M P/ A x M P I M P I M P 
D ose F or m ul ati o n B ul k p o w der f or e xte m p or a ne o us 
pre parati o n of oral s us pe nsi o n sB ul k p o w der f or e xte m p or a ne o us 
pre parati o n of oral s us pe nsi o n s
U nit D ose Stre n gt h(s) m g 0 m g 
R o ute of A d mi nistr ati o n Oral Oral 0 9 0 1 7 7 e 1 9 e 0f 3 af c\ A p pr o v e d\ A p pr o v e d O n: 1 9- J ul- 2 0 2 3 0 1: 5 5 ( G M T) C CI 
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 14Study Arm(s)
Arm Title Cohort 1 Cohort 2 (Optional) Cohort 3 (Optional)
Arm Description Participants may receive up 
to 5 dose levels of PF-06954522 and matching 
placebo. Doses will be 
administered as oral suspensions as escalating single doses to be determined.Participants may receive up 
to 4 dose levels of PF-06954522 and matching 
placebo. Doses will be 
administered as oral suspensions as escalating single doses to be determined.Participants may receive up 
to 3 dose levels of PF-06954522 and matching 
placebo. Doses will be 
administered as oralsuspensions as escalating single doses to be determined.
Assessment of the safety, tolerability, and PK after each single dose level will be conducted 
before escalating to the next dose level. The dose/exposure-escalation increments are planned to be up to approximate semi-logarithmic increases in exposure from the previous highest dose level that has been evaluated. The actual dose levels, target exposures, and/or dose level increments may be adjusted during the study based on emerging human safety, tolerability, and PK data, but projected exposures will not exceed the predefined human exposure limits.
Statistical Methods: The sample size has been chosen based on the need to minimize first 
exposure to humans of a new chemical entity and the requirement to conduct adequate safety, tolerability, and PK assessments at each dose level. All safety analyses will be performed on the safety analysis set, which is defined as all participants randomly assigned to study intervention and who take at least 1 dose of study intervention. Participants will be analyzed according to the study intervention they actually received. Safety data will be presented in tabular and/or graphical format and summarized descriptively, where appropriate. The plasma PK parameters for PF-06954522 following oral dose administration will be derived from the plasma concentration ‑time profiles. Plasma PK parameters and 
concentrations of PF-06954522 will be descriptively summarized by [CONTACT_2715] (and fasting condition, and ethnicity, if appropriate) and nominal time, as appropriate.
Ethical Considerations:The participants in this study are not expected to obtain any specific benefit beyond 
contributing to the process of developi[INVESTIGATOR_336243]. They will be expected to commit time and may experience some discomfort while undergoing study procedures. However, they will receive close monitoring of their safety via safety monitoring procedures (eg, physical examinations, 12-lead ECGs, vital signs) as outlined in this protocol. Based on the totality of available nonclinical data and taking into account the measures to minimize risk to study participants, the overall benefit/risk profile supports clinical testing of PF-[ADDRESS_415364] to diet and exercise for the treatment type 2 diabetes mellitus (T2DM).
1.2. Schema
A sample study design schematic is presented in Figure 1 . It should be noted that this is for 
illustrative purposes, only. 090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 212. INTRODUCTION
GLP-1 is a neuroendocrine hormone that is predominantly released from the small intestine 
in response to food intake.[ 1] Activation of the GLP-1 receptor stimulates insulin release, 
inhibits glucagon secretion in a glucose-dependent manner, and delays gastric emptying.[ 2,3]
In addition, GLP-1 has been shown to increase satiety and suppress food intake.[ 4]
PF-[ADDRESS_415365] more than 500 million adults (aged 20-79) worldwide.[ 5]T h e  
increase in the global prevalence of T2DM is largely attributed to rising rates of excess body weight and obesity.[ 6] T2DM is characterized by [CONTACT_30361], a disorder in which cells 
do not respond effectively to insulin, resulting in higher blood glucose levels. Elevated blood glucose levels and increasing severity of insulin resistance result in the need for more insulin 
over time, eventually resulting in progressive pancreatic #-cell failure.[ 7] Patients with 
poorly controlled T2DM have an increased risk of developi[INVESTIGATOR_95457], including nephropathy, neuropathy, retinopathy, and cardiovascular disease; and are at [ADDRESS_415366] diabetes.[ 8] While existing pharmacological 
options for the treatment of diabetes may provide satisfactory glycemic control for some patients, there remain a large number of patients who do not achieve target HbA1c levels, suggesting a need for additional therapeutic options which minimize patient burden such as oral therapi[INVESTIGATOR_014]. 
Currently available GLP-1R agonists have demonstrated robust efficacy for glycemic
control, weight loss, and CV safety, with several agents having shown a benefit in CV outcomes.[ 9] Most available GLP-1R agonist treatment options are injected once weekly 
subcutaneously.[ 10],[11] Injectable therapi[INVESTIGATOR_336244], 
whereas oral options are preferred by [CONTACT_336260]. Only one GLP-1R agonist (Rybelsus ∃; 
oral semaglutide) is currently commercially available for oral administration. However, oral 
semaglutide has strict administration requirements (food and water restrictions) and has 
limitations due to its low bioavailability[ 12], making it less convenient than an agent without 
such restrictions. A novel oral small molecule GLP-1R agonist that may further improve glycemic control, reduce HbA1c levels, and decrease food intake and body weight compared to existing oral GLP-1R agonist, without any administration restrictions, is expected to be a preferred therapeutic option for patients with T2DM and their physicians. Another small 090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 25treatment of patients with T2DM. As of the date of this protocol, no specific human risks 
have been identified; postulated risks based on nonclinical studies with PF-[ADDRESS_415367] been found to be well tolerated with an acceptable safety profile ( Section 4.2 and Section 4.3 ). In
addition, this study will employ stoppi[INVESTIGATOR_336245] ( Section 6.6.1 ) and 
includes standard, intensive, inpatient monitoring of the participants following administration of single, oral doses of the study intervention as outlined in the SoA.
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of PF-06954522 may be found in the IB, which is the SRSD for this study.Refer to the Study Intervention(s) table in Section 6.1 for a complete description of SRSDs.090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 262.3.1. Risk Assessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Study Intervention(s) PF-[ADDRESS_415368] labeling for 
injectable GLP-1R agonists (ie, liraglutide, exenatide, semaglutide and dulaglutide).Study includes inpatient monitoring of the 
participants following administration of a single dose of the study intervention.
Participants are monitored to prevent 
potential sequelae of any severe gastrointestinal reactions, eg, dehydration.
HypoglycemiaClinical trials with injectable GLP-1R agonists have not
demonstrated an increased risk for hypoglycemia. However, when administered in combination with anti-diabetic agents that are known to have an increased risk of hypoglycemia 
(such as insulin or sulfonylureas), an increased risk for 
hypoglycemia was observed.The participants enrolled will not have 
diabetes and will not be receiving anti-diabetic agents. 
Study includes inpatient monitoring of the 
participants following administration of a 
single dose of the study intervention.
Increased heart rate and decreased PR intervalBased on the product labeling for the injectable GLP-1R 
agonist liraglutide for obesity, mean increases in resting heart rate ranged 2 to 3 bpm in clinical trials, with some participants experiencing greater increases in resting heart rate, up to 10-20 bpm. Increased heart rate and decreased 
PR interval was observed in a single-dose NHP study of PF-
06954522.Study includes inpatient monitoring of the 
participants through periodic vital sign assessment, ECGs and telemetry following administration of a single dose of the study intervention.
Other potential risks associated with long-term dosing of marketed GLP-1R agonists include thyroid C-cell tumors, pancreatitis, impairment in renal function, diabetic retinopathy 
complications, suicidal ideation/behavior and 
acute gallbladder disease.These potential risks are based on product labeling for 
injectable GLP-1R agonists (ie, liraglutide, dulaglutide, exenatide and semaglutide).This is a single dose study in healthy 
participants. 
Participants with a personal or family 
history of MTC or MEN2; with acute 
pancreatitis or a history of chronic 
pancreatitis are not eligible for study entry.
Study includes inpatient monitoring and 
safety laboratory surveillance (eg,calcitonin, amylase, lipase, eGFR) of the 090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 27Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Study Intervention(s) PF-06954522
participants following administration of a 
dose of the study intervention.
Increased transaminases (eg, ALT & AST) Elevated ALT and AST were observed in a subset of 
participants in the lotiglipron clinical studies following multiple dose administration. Study includes inpatient monitoring and 
safety laboratory surveillance (eg, LFTs) of 
the participants following administration of 
a dose of the study intervention.090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
P F -0 6 9 5 4 5 2 2 
Pr ot oc ol C4 0 0 1 0 0 1 
Fi nal Pr ot oc ol, 1 7 J ul y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol T e m plate ( 1 4 A pril 2 0 2 3) 
Pa ge [ADDRESS_415369] u d y  are n ot e x pecte d t o o btai n a n y  s pecific be nefit be y o n d 
c o ntri b uti n g t o t he pr ocess of de vel o pi n g ne w t hera pi[INVESTIGATOR_014] i n a n area of u n met nee d. 
2. 3. 3. O ver all Be nefit /Ris k C o ncl usi o n 
Base d o n all a vaila ble data o n P F - [ADDRESS_415370] u d y partici pa nts , t he p ote ntial 
ris ks i de ntifie d i n ass ociati o n wit h P F -0 6 9 5 4 5 2 2 are j ustifie d b y  t he a ntici pate d be nefits t hat 
ma y  be aff or de d t o partici pa nts wit h T 2 D M .
3. O B J E C TI V E S A N D E N D P OI N T S 
O bjecti ves E n d p oi nts 
Pri m ar y : Pri m ar y : 
T o e val uate t he safet y a n d t olera bilit y of si n gle oral 
d oses of P F - 0 6 9 5 4 5 2 2, a d mi nistere d t o healt h y a d ult 
partici pa nts. Assess me nt of A Es, safet y la b orat or y tests, vital si g ns 
( bl o o d press ure ,p ulse rate , te m perat ure ), car diac 
tele metr y a n d sta n dar d 1 2 -lea d E C Gs , a n d P E .
Sec o n d ar y: Sec o n d ar y: 
T o c haracterize plas ma P K of P F -0 6 9 5 4 5 2 2 f oll o wi n g 
si n gle oral d oses of P F -0 6 9 5 4 5 2 2 a d mi nistere d t o 
healt h y a d ult partici pa nts. P F - 0 6 9 5 4 5 2 2 P K para meters: A U C la st , C ma x, T ma x , a n d if 
data per mit ,A U C i nf a n d t½.
Terti ar y/ E x pl or at or y: Terti ar y/ E x pl or at or y: 
T o f urt her c haracterize plas ma P K of P F - 0 6 9 5 4 5 2 2 
f oll o wi n g si n gle oral d oses of P F -0 6 9 5 4 5 2 2 
a d mi nistere d t o healt h y a d ult partici pa nts. 
O pti o nal: t o c haracterize t he effect of f o o d ( hi g h -fat 
brea kfast) o n t he plas ma P K of P F - 0 6 9 5 4 5 2 2 
f oll o wi n g si n gle oral d oses of P F -0 6 9 5 4 5 2 2 i n 
healt h y a d ult partici pa nts. 
O pti o nal: t o e x pl ore t he safet y, t olera bilit y, a n d 
plas ma P K of P F -0 6 9 5 4 5 2 2 i n healt h y a d ult Ja pa nese 
partici pa nts. A d diti o nal P F -0 6 9 5 4 5 2 2 P K para meters: A U C last ( d n), 
Cma x( d n), a n d if data per mit, A U C i nf ( d n), C L/ F ,a n d 
Vz/ F. 
P F - 0 6 9 5 4 5 2 2 P K para meters after a hi g h- fat meal: 
A U C last , C ma x, Tma x a n d if data per mit ,A U C i nf , C L/ F, 
Vz/ F a n d t ½.
Assess me nt of A Es, safet y la b orat or y tests, vital si g ns 
( bl o o d press ure, p ulse rate a n d te m perat ure), sta n dar d 
1 2 -lea d E C Gs a n d t he f oll o wi n g P F -0 6 9 5 4 5 2 2 P K 
para meters i n Ja pa nese partici pa nts : A U C last , C ma x, 
Tma x , a n d if data per mit ,A U C i nf , C L/ F , V z/ F a n d t ½.
4. S T U D Y D E SI G N 
4. 1. O ver all Desi g n 
T his FI H st u d y  has a d o u ble - bli n de d (i n vesti gat or- a n d partici pa nt bli n de d), s p o ns or- o pe n, 
ra n d o mize d, si n gle -asce n di n g oral d ose, u p t o 5peri o d cr oss o ver, place b o s u bstit uti o n desi g n 
i n 1c o h ort ( C o h ort 1) of healt h y  a d ult partici pa nts. A n o pti o nal c o h ort of healt h y  a d ult 
partici pa nts ( C o h ort 2) i n u p t o 4 cr oss o ver peri o ds, ma y be i ncl u de d t o per mit assess me nt of 
a n y  of t he f oll o wi n g: re peat of a pre vi o usl y  a d mi nistere d d ose le vel; st u d y i n g a d diti o nal d ose 
le vels as dictate d b y t he e val uate d safet y, t olera bilit y ,or P K of earlier d ose le vels; or a n y  
ot her assess me nt nee de d t o meet t he o b jecti ves of t his st u d y . A sec o n d o pti o nal c o h ort 
( C o h ort 3) e nr olli n g Ja pa nese partici pa nts i n u p t o 3 cr oss o ver peri o ds, ma y  be i ncl u de d. 0 9 0 1 7 7 e 1 9 e 0f 3 af c\ A p pr o v e d\ A p pr o v e d O n: 1 9- J ul- 2 0 2 3 0 1: 5 5 ( G M T) C CI 
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 29A total of approximately [ADDRESS_415371] been investigated and deemed sufficiently safe in previous cohort(s). Full details will be provided to the investigator in writing, prior to dosing of this cohort. Participants who discontinue for non-safety reasons prior to completion of the study may be replaced, at the discretion of the PI [INVESTIGATOR_38107]. The replacement participant(s) may or may not be required to complete all periods of the cohort in which they are participating at the discretion of the PI [INVESTIGATOR_38107].
Participants will be screened within [ADDRESS_415372] dose of study intervention (Period 1, 
Day 1). Participants will be admitted to the CRU on Day -[ADDRESS_415373] 7 days. The washout interval may be increased based on data emerging from previous cohorts/periods. Dose escalation will occur only after the previous dose level was demonstrated to be well tolerated with an acceptable safety profile based on review of the emerging safety and PK data (see Section 6.6.1 ). Dose levels will be escalated to bracket the 
expected clinical dose range, but the projected exposures will not exceed the predefined 
human exposure limits. An on-site follow-up visit and a telephone follow-up contact [CONTACT_8965] 7-[ADDRESS_415374] may be substituted with an on-site visit in case of additional follow-up of open AEs or clinically significant laboratory findings. Therefore, the total planned duration of participation, from the Screening visit to the follow-up phone call, will be approximately 13 weeks for Cohort 1, 12 weeks for optional Cohort 2 and 11 weeks for optional Cohort 3 (if performed as a 3-way crossover).
Dosing of study intervention is anticipated to occur following a fast of at least 10 hours. Dose 
administration may also occur in the fed state (following a high-fat breakfast, seeSection 5.3.2 ), in order to explore any potential food effect on PF-06954522 PK. If this 
assessment is conducted, it is anticipated that the study intervention will be administered in 090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
P F -0 6 9 5 4 5 2 2 
Pr ot oc ol C4 0 0 1 0 0 1 
Fi nal Pr ot oc ol, 1 7 J ul y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol T e m plate ( 1 4 A pril 2 0 2 3) 
Pa ge [ADDRESS_415375] u die d was selecte d t o acc o u nt f or u ncertai nties i n t he pr ojecte d C eff 
a n d t he pr ojecte d t hera pe utic d ose, w hile als o brac keti n g t he e x pecte d cli nicall y  eff icaci o us 
d ose ra n ge i n h u ma ns f or cli nicall y  rele va nt p har mac ol o gical acti vit y a n d pr o vi di n g safet y 
c o vera ge f or a wi de ra n ge of P F - 0 6 9 5 4 5 2 2 d oses .
T he pr ojecte d e x p os ures of P F -0 6 9 5 4 5 2 2 f or eac h pla n ne d d ose le vel, as well as t he 
c orres p o n di n g safet y mar gi ns relati ve t o h u ma n e x p os ure li mit s are s u m marize d i n Ta ble 3. 
T a ble 3. Pre dicte d H u m a n E x p os ure a n d S afet y M ar gi ns F oll o wi n g 
A d mi nistr ati o n of Si n gle Or al D oses of P F- 0 6 9 5 4 5 2 2 
D ose ( m g) aPre dicte d H u m a n P F -0 6 9 5 4 5 2 2 E x p os ure Pre dicte d S afet y M ar gi n 
T ot al C m a xb
( n g/ m L) T ot al 
A U C 2 4 b
( n g• h/ m L) U n b o u n d 
Cm a xc
( n g/ m L) U n b o u n d 
A U C 2 4 c
( n g• h/ m L) Cm a xdA U C 2 4 d
a. Base d o n t he a vaila ble safet y, t olera bilit y a n d P K data, d ose escalati o n ma y be a dj uste d t o d oses ot her t ha n 
t h ose o utli ne d a b o ve wit h i nter me diate d oses e val uate d i nstea d of or i n a d diti o n t o t he pla n ne d d ose le vels wit h 
i ncre me nts bei n g a p pr o xi matel y ≤ ½- l o g (ie, a p pr o xi matel y 3. 3 -f ol d) w hile al wa ys f oll o wi n g d ose escalati o n a n d 
st o p pi n g r ules o utli ne d i n Secti o n 6. 6. [ADDRESS_415376] -or der a bs or pti o n a n d 
eli mi nati o n. T he pr ojecte d h u ma n P F -0 6 9 5 4 5 2 2 P K para meters o utli ne d i n Secti o n 4. 3. 1 were use d i n t he 
m o del. 
c. U n b o u n d e x p os ure val ues calc ulate d after c orrecti n g f or plas ma pr otei n bi n di n g i n h u ma ns ( ). 
d. Safet y mar gi ns at t he pr o p ose d d oses were calc ulate d base d o n t he h u ma n e x p os ure li mits (t otal 
) w hic h were base d o n t he N O A E L e x p os ures i n 
t he 8-wee k N H P G L P t o xicit y st u d y after c orrecti n g f or s pecies differe nce i n plas ma pr otei n bi n di n g. 
Be y o n d t he starti n g d ose, t he pla n ne d d ose escalati o n pr oce d ure will be dictate d b y  t he r ules 
s u m marize d i n Secti o n 6. 6. 1 .Assess me nt of t he safet y , t olera bilit y , a n d P K after eac h si n gle 
d ose le vel will be c o n d ucte d bef ore escalati n g t o t he ne xt d ose le vel. T he 
d ose/e x p os ure -escalati o n i ncre me nts are pla n ne d t o be u p t o a p pr o xi mate se mi-l o garit h mic 
i ncreases i n e x p os ure fr o m t he pre vi o us hi g hest d ose le vel t hat has bee n e val uate d. If 
e x p os ure e xcee ds t he pr ojecte d t hera pe utic ra n ge, or if c ha n ges i n safet y para meters are 
o bser ve d, s maller d ose -escalati o n ste ps m a y  be i m ple me nte d. D ose -escalati o n is e n visi o ne d 
t o pr ocee d u p t o t he hi g hest d ose dee me d t o be well t olerate d wit h a n acce pta ble safet y 
pr ofile, ac hie ve me nt of plas ma e x p os ures e q ui vale nt t o t he P K st o p pi n g li mits (see 
Secti o n 6. 6. 1 ). 
T he act ual d ose le vels, tar get e x p os ures, a n d/ or d ose le vel i ncre me nts ma y  be a dj uste d 
( hi g her or l o wer) d uri n g t he st u d y  base d o n e mer gi n g h u m a n safet y, t olera bilit y , a n d P K 
data, b ut pr ojecte d e x p os ures will n ot e xcee d t he pre defi ne d h u ma n e x p os ure li mits. D ose 
le vels ma y  als o be re peate d if warra nte d. 0 9 0 1 7 7 e 1 9 e 0f 3 af c\ A p pr o v e d\ A p pr o v e d O n: 1 9- J ul- 2 0 2 3 0 1: 5 5 ( G M T) C CI C CI 
C CI 
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 34When the assessment of the effect of food on the PK of PF-06954522 is conducted, the dose 
level will be selected based on emerging safety, tolerability, and PK data from previous periods of this study. This will be assessed at a dose level that has been previously administered fasted within the same cohort (as outlined in Section 4.2 ).
4.4. End of Study Definition
The end of the study is defined as the date of the last visit of the last participant in the study 
or last scheduled procedure shown in the SoA for the last participant in the trial globally.
A participant is considered to have completed the study if they have completed all periods of 
the study, including the last visit or the last scheduled procedure shown in the SoA and any 
requested unplanned visits.
5. STUDY POPULATION
This study can fulfill its objectives only if appropriate participants are enrolled, including 
participants across diverse and representative racial and ethnic backgrounds. If a prescreening tool is utilized for study recruitment purposes, it will include collection of information that reflects the enrollment of a diverse participant population including, where permitted under local regulations, age, sex, race, and ethnicity. The following eligibility criteria are designed to select participants for whom participation in the study is considered appropriate. All relevant medical and nonmedical conditions should be taken into consideration when deciding whether a particular participant is suitable for this protocol.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1. Inclusion Criteria
Participants are eligible to be included in the study only if all of the following criteria apply:
Age and Sex:
1. Male and female participants of non-childbearing potential aged 18 to 65 years, 
inclusive, at screening who are overtly healthy as determined by [CONTACT_336261], physical examination, laboratory tests, and cardiac monitoring. 
Refer to Appendix 4 for reproductive criteria for male ( Section 10.4.1 ) and female 
(Section 10.4.2 ) participants.
Other Inclusion Criteria:
2. BMI of 16-30.5 kg/m
2; and a total body weight >50 kg (110 lb) .
Japanese participants only: participants enrolling as Japanese must have 
4 biological Japanese grandparents who were born in Japan. A lower entry weight of 090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
P F -0 6 9 5 4 5 2 2 
Pr ot oc ol C4 0 0 1 0 0 1 
Fi nal Pr ot oc ol, 1 7 J ul y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol T e m plate ( 1 4 A pril 2 0 2 3) 
Pa ge [ADDRESS_415377] y :
Me dic al C o n diti o ns: 
1. E vi de nce or hist or y  of cli nicall y  si g nifica nt he mat ol o gical, re nal, e n d ocri ne, 
p ul m o nar y , gastr oi ntesti nal, car di o vasc ular, he patic, ps y c hiatric, ne ur ol o gic al , or 
aller gic disease (i ncl u di n g dr u g aller gies, b ut e xcl u di n g u ntreate d, as y m pt o matic, 
seas o nal aller gies at t he ti me of d osi n g ). 
A n y  c o n diti o n p ossi bl y  affecti n g dr u g a bs or pti o n (e g, gas trect o m y , 
c h olec y stect o m y). 
Hist or y  of HI V i nfecti o n, he patitis B, or he patitis C; p ositi ve testi n g f or HI V , 
H Bs A g, H Bc A b, or H C V A b. Hist or y  of h e patitis B vacci nati o n wit h a n is olate d 
p ositi ve H Bs A b res ult is all o we d. 
2. Pers o nal or fa mil y hist or y of M T C or M E N 2, or partici pa nts wit h s us pecte d M T C per 
t he i n vesti gat or’s j u d ge me nt. 
3. A n y  me dical or ps yc hi atric c o n diti o n i ncl u di n g rece nt ( wit hi n t he past ye ar) or acti ve 
s uici dal i deati o n /be ha vi or or la b orat or y  a b n or malit y  or ot her c o n diti o ns t hat ma y  
i ncrease t h e ris k of st u d y partici pati o n or , i n t he i n vesti gat or’s j u d g me nt, ma ke t he 
partici pa nt i na p pr o priate f or t he st u d y .
Pri or/ C o nc o mit a nt T her a p y: 
4. Use of prescri pti o n or n o n prescri pti o n dr u gs a n d dietar y a n d her bal s u p ple me nts 
wit hi n 7 da y s or 5 half -li ves ( w hic he ver is l o n ger) pri or t o t he first d ose of st u d y  
i nter ve nti o n wit h t he e xce pti o n of  
w hic h are pr o hi bite d wit hi n [ADDRESS_415378] u d y  
i nter ve nti o n . ( Refer t o Secti o n 6. 9 Pri or a n d C o nc o mita nt T hera p y f or a d diti o nal 
details ). 0 9 0 1 7 7 e 1 9 e 0f 3 af c\ A p pr o v e d\ A p pr o v e d O n: 1 9- J ul- 2 0 2 3 0 1: 5 5 ( G M T) C CI 
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 36Prior/Concurrent Clinical Study Experience:
5. Previous administration with an investigational product (drug or vaccine) within 
30 days (or as determined by [CONTACT_19970]) or [ADDRESS_415379] dose of study intervention used in this study (whichever is longer). Participation in studies of other investigational products (drug or vaccine) at any time during their participation in this study.
Diagnostic Assessments:6. A positive urine drug test at screening or admission.7. Screening supi[INVESTIGATOR_30991] ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic) for 
participants <60 years; and ≥150/90 mm/Hg for participants ≥[ADDRESS_415380]. If systolic BP is ≥140 or 150 mm Hg (based on age) 
or diastolic ≥90 mm Hg, the BP should be repeated 2 more times and the average of 
the 3 BP values should be used to determine the participant’s eligibility. 
8. Renal impairment as defined by [CONTACT_234129] <75 mL/min/1.73 m². Based upon 
participant age at screening, eGFR is calculated using the recommended CKD-EPI [INVESTIGATOR_336246] 10.7.2 to determine eligibility (Screat-based formula) and to 
provide a baseline (Screat-Scys combined formula) to quantify subsequent kidney safety events. For eligibility assessment based upon estimated renal function, the higher of the screening and baseline eGFR values may be used.
9. Standard 12-lead ECG at Screening that demonstrates clinically relevant 
abnormalities that may affect participant safety or interpretation of study results (eg, QTcF >[ADDRESS_415381]- degree AV block, or serious bradyarrhythmias or tachyarrhythmias). If QTcFexceeds 450 ms, or QRS exceeds 120 ms, the ECG should be repeated twice and the average of the 3 QTcF or QRS values used to determine the participant’s eligibility.Computer-interpreted ECGs should be overread by a physician experienced in reading ECGs before excluding a participant.
10. Participants with ANY of the following abnormalities in clinical laboratory tests at 
screening, as assessed by [CONTACT_1758]-specific laboratory and confirmed by a single 
repeat test, if deemed necessary: 
!ALT, AST, or bilirubin ≥1.05 × ULN. Participants with an elevated total bilirubin 
consistent with Gilbert ’s Disease may have a direct bilirubin measured and would 
be eligible for this study provided the direct bilirubin level is ≤ULN;
!TSH %ULN 
!HbA1c ≥6.5%;090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 37!Hematuria as defined by ≥1+ heme on urine dipstick;
!Albuminuria as defined by [CONTACT_336262]/creatinine ratio (UACR) >30 mg/g.
Other Exclusion Criteria:
11. History of alcohol abuse or binge drinking and/or any other illicit drug use or 
dependence within 6 months of Screening. Binge drinking is defined as a pattern of 5 (male) and 4 (female) or more alcoholic drinks in about 2 hours. As a general rule, alcohol intake should not exceed 14 units per week (1 unit = 8 ounces (240 mL) beer, 1 ounce (30 mL) of 40% spi[INVESTIGATOR_17040], or 3 ounces (90 mL) of wine).
12. Use of tobacco/nicotine containing products in excess of the equivalent of 
5 cigarettes/day or 2 chews of tobacco/day.
13. Investigator site staff directly involved in the conduct of the study and their family 
members, site staff otherwise supervised by [CONTACT_093], and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
5.3. Lifestyle Considerations
The following guidelines are provided:
5.3.1. Contraception
The investigator or their designee, in consultation with the participant, will confirm that 
the participant is utilizing an appropriate method of contraception for the individual participant and their partner(s) from the permitted list of contraception methods (see Appendix 4 ,Section 10.4.4 ) and will confirm that the participant has been instructed in 
its consistent and correct use. The investigator or designee will advise the participant to seek advice about the donation and cryopreservation of germ cells prior to the start of study intervention, if applicable.
At time points indicated in SoA, the investigator or designee will inform the participant 
of the need to use highly effective contraception consistently and correctly and document the conversation and the participant’s affirmation in the participant’s chart. Participants need to affirm their consistent and correct use of at least [ADDRESS_415382] the participant to call immediately if 
the selected contraception method is discontinued and document the requirement to use an alternate protocol-specified method, including if the participant will no longer use abstinence as the selected contraception method, or if pregnancy is known or suspected in the participant or partner.090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 385.3.2. Meals and Dietary Restrictions
!Participants must abstain from all food and drink (except water) for at least 8 hours 
prior to all safety laboratory evaluations.
!Participants must abstain from all food and drink (except water) for at least 10 hours 
prior to the collection of the predose PK sample.
!Water is permitted until 1 hour prior to study intervention administration. Water may 
be consumed without restriction beginning 1 hour after dosing. Noncaffeinated drinks (except grapefruit or grapefruit-related citrus fruit juices (see below) may be consumed with meals and the evening snack .
Dosing under fasted conditions (Day 1 only):
!The standard morning breakfast will not be offered on Day 1. Participants will remain 
fasted for 4 hours following dosing.
Dosing under fed conditions (Day 1 only):
!A morning meal will be served to participants approximately 30 minutes prior to 
dosing and is expected to be completed approximately 10 minutes prior to dosing. 
Participants will be encouraged to consume the entire meal.
!For planned assessment of food effect, this morning meal will be a high-fat 
(approximately 50% of total caloric content of the meal) and high-calorie (approximately 800-1000 calories) breakfast. The breakfast will consist of approximately [ADDRESS_415383] meal would be: 2 eggs fried in butter, 2 strips of bacon (or 50 g of meat or sausage), [ADDRESS_415384] with butter, 4 ounces (approximately 112 grams) of hash brown potatoes, and 8 fluid ounces (240 mL) of whole milk.
!A standard breakfast may be provided during other study periods/cohorts, if 
deemed necessary to meet study objectives (see Section 4.1 ). If this is the case, 
details will be provided to the investigator in writing. 
!While inpatient, the meals consumed are expected to follow the restrictions outlined 
below:
!No food will be allowed for at least [ADDRESS_415385]-dose.
!Lunch will be provided approximately 4 hours after dosing.
!Dinner will be provided approximately 9 to 10 hours after dosing.090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 39!Participants may delay or skip postdose meals or be offered an alternative meal in 
case of nausea or vomiting. In such cases, the proportion of each meal consumed by [CONTACT_336263]. 
!An evening snack may be permitted.
!On non-dosing days while inpatient, as appropriate, standard morning meal, 
lunch, and evening meal (along with an evening snack) are to be provided at a similar clock time to the clock time when these meals are offered on the dosing day.
!Participants will refrain from consuming red wine, grapefruit, or grapefruit 
related-citrus fruits (eg, Seville oranges, pomelos, fruit juices) from [ADDRESS_415386] dose of study intervention until collection of the final PK blood sample. 
!With the exception of the standard high-fat, high-calorie breakfast to be consumed 
during food effect assessment, while participants are confined, their total daily 
nutritional composition should be approximately 55% carbohydrate, 30% fat, and 15% protein, except when the study intervention is administered with high-fat, high-calorie breakfast. The daily caloric intake per participant should not exceed approximately 3200 kcal.
5.3.3. Caffeine, Alcohol, and Tobacco
!Participants will abstain from caffeine -containing products for 24 hours prior to the 
start of dosing until collection of the final PK sample of each study period. 
!Participants will abstain from alcohol for 24 hours prior (or as specified above for red 
wine) to admission to the CRU and continue abstaining from alcohol until collection 
of the final PK sample of each study period. Participants may undergo an alcohol breath test or blood alcohol test at the discretion of the investigator.
!Participants will abstain from the use of tobacco- or nicotine -containing products for 
24 hours prior to dosing and during confinement in the CRU.
5.3.4. Activity
!Participants will abstain from strenuous exercise (eg, heavy lifting, weight training, 
calisthenics, aerobics) for at least 48 hours prior to each blood collection for clinical laboratory tests. Walking at a normal pace will be permitted;
!In order to standardize the conditions on PK sampling days, participants will be 
required to refrain from lying down (except when required for BP, pulse rate, and ECG measurements), eating, and drinking beverages other than water during the first 4 hours after dosing;090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
P F -0 6 9 5 4 5 2 2 
Pr ot oc ol C4 0 0 1 0 0 1 
Fi nal Pr ot oc ol, 1 7 J ul y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol T e m plate ( 1 4 A pril 2 0 2 3) 
Pa ge 4 0 Partici pa nt s will be c o nfi ne d t o t he pr oce d ure r o o m f or t he first 4 h o urs after d osi n g 
o n Da y 1 d uri n g c o nti n u o us car diac m o nit ori n g, e xce pt t o use t he bat hr o o m. After 
t his, if t he e q ui p me nt s et u p all o ws, partici pa nt s ma y  be a m b ulat or y  d uri n g t he E C G 
m o nit ori n g peri o d, b ut s h o ul d n ot e n ga ge i n stre n u o us acti vities. If e q ui p me nt d oes 
n ot all o w a m b ulati o n, a p pr o priate acc o m m o dati o ns will be ma de b y  t he i n vesti gat or 
site t o facilitate c o nti n u o us m o nit ori n g ( e g , be dsi de uri nals s h o ul d be pr o vi de d t o 
acc o m m o date partici pa nt s’ e xcret or y  nee ds) .
5. 4. Scree n F ail ures 
Scree n fail ures are defi ne d as partici pa nts w h o c o nse nt t o partici pate i n t he cli nical st u d y  b ut 
are n ot s u bse q ue ntl y  e nr olle d i n t he st u d y .Sc ree n fail ure data are c ollecte d a n d re mai n as 
s o urce a n d are n ot re p orte d o n t he C R F .
I n di vi d uals w h o d o n ot meet t he criteria f or partici pati o n i n t his st u d y  (scree n fail ure) ma y  be 
rescree ne d at t he discreti o n of t he PI  i n c o ns ultati o n wit h t he me dical m o nit or . 
6. S T U D Y I N T E R V E N TI O N( S ) A N D C O N C O MI T A N T T H E R A P Y 
St u d y  i nter ve nti o ns are all pres pecifie d i n vesti gati o nal a n d, me dical de vices, a n d ot her 
i nter ve nti o ns (e g, s ur gical a n d be ha vi oral) i nte n de d t o be a d mi nistere d t o t he st u d y  
partici pa nts d uri n g t he st u d y  c o n d uct. 
F or t he p ur p oses of t his pr ot oc ol, st u d y  i nter ve nti o n refers t o P F -[ADDRESS_415387] u d y I nter ve nti o n(s) A d mi nistere d 
St u d y I nter ve nti o n(s) 
I nter ve nti o n 
N a me P F -[ADDRESS_415388] b o 
I M P or 
NI M P/ A x M P I M P I M P 
D ose 
F or m ul ati o n B ul k p o w der f or e xte m p ora ne o us pre parati o n of 
oral s us pe nsi o ns B ul k p o w der f or e xte m p ora ne o us pre parati o n of 
oral s us pe nsi o ns 
U nit D ose 
Stre n gt h(s) Pl a n ne d s us pe nsi o n d oses ra n gi n g fr o m 
m g 0 m g 
D os a ge Le vel(s) Si n gle asce n di n g d oses  m g (see 
Secti o n 1. 2 a n d Secti o n 4. 3 . 4 ) 0 m g 
R o ute of 
A d mi nistr ati o n Oral Oral 0 9 0 1 7 7 e 1 9 e 0f 3 af c\ A p pr o v e d\ A p pr o v e d O n: 1 9- J ul- 2 0 2 3 0 1: 5 5 ( G M T) C
C
C CI 
P F -0 6 9 5 4 5 2 2 
Pr ot oc ol C4 0 0 1 0 0 1 
Fi nal Pr ot oc ol, 1 7 J ul y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol T e m plate ( 1 4 A pril 2 0 2 3) 
Pa ge [ADDRESS_415389] u d y I nter ve nti o n(s) 
S o urci n g Pr o vi de d b y t he s p o ns or Pr o vi de d b y t he s p o ns or 
P ac k a gi n g a n d 
L a beli n g St u d y i nter ve nti o n will be pr o vi de d i n b ul k 
p o w der f or e xte m p ora ne o us pre parati o n of oral 
s us pe nsi o ns . Eac h b ottle will be la bele d as 
re q uire d per c o u ntr y re q uire me nt. St u d y i nter ve nti o n will be pr o vi de d i n b ul k 
p o w der f or e xte m p ora ne o us pre parati o n of oral 
s us pe nsi o ns. Eac h b ottle will be la bele d as 
re q uire d per c o u ntr y re q uire me nt. 
S R S D I B I B 
St u d y Ar m(s) 
A r m  Title C o h ort 1 C o h ort 2 ( O pti o nal) C o h ort 3 ( O pti o nal) 
A r m  Descri pti o n Partici pa nts ma yrecei ve 
u p t o [ADDRESS_415390] b o will be pr o vi de d b y [COMPANY_007] as b ul k p o w ders f or e xte m p ora ne o us 
pre parati o n of oral s us pe nsi o ns at t he C R U. 
P F -[ADDRESS_415391] b o will be prese nte d t o t he partici pa nt s i n i n di vi d ual d osi n g 
c o ntai ners. 
6. 1. 1. A d mi nistr ati o n 
F or faste d peri o ds: 
Foll o wi n g a n o ver ni g ht fast of at least [ADDRESS_415392] u d y  
i nter ve nti o n at a p pr o xi matel y  0 8 0 0 h o urs ( pl us or mi n us 2 h o urs) wit h o ut brea kfast 
o n Da y  1. 
F or fe d peri o d(s): 
F oll o wi n g a n o ver ni g ht fast of at least [ADDRESS_415393] u d y  i nter ve nti o n a p pr o xi matel y  1 0 mi n utes after c o m pleti o n of t he meal at 
a p pr o xi matel y  0 8 0 0 h o urs ( pl us or mi n us 2 h o urs). 0 9 0 1 7 7 e 1 9 e 0f 3 af c\ A p pr o v e d\ A p pr o v e d O n: 1 9- J ul- 2 0 2 3 0 1: 5 5 ( G M T) C CI 
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 42On Day [ADDRESS_415394].
In order to standardize the conditions on PK sampling days, all participants will be required 
to refrain from lying down (except when required for BP, pulse rate, and ECG measurements), eating, and drinking beverages other than water during the first 4 hours after dosing.
Administration of study intervention(s) at the site will be performed by [CONTACT_336264], state, and institutional guidance. 
Following administration of study intervention(s) at the site, participants will be observed for 
up to [ADDRESS_415395] confirm that appropriate conditions (eg, 
temperature) have been maintained during transit for all study interventions received and any discrepancies are reported and resolved before use of the study intervention. 
2. Only participants enrolled in the study may receive study intervention and only 
authorized site staff may supply, prepare, and/or administer study intervention.
3. All study interventions must be stored in a secure, environmentally controlled, and 
monitored (manual or automated recording) area in accordance with the labeled storage conditions with access limited to the investigator and authorized site staff. At a minimum, daily minimum and maximum temperatures for all site storage locations must be documented and available upon request. Data for nonworking days must indicate the minimum and maximum temperatures since previously documented upon return to business.
4. Any excursions from the study intervention label storage conditions should be 
reported to [COMPANY_007] upon discovery along with actions taken. The site should actively pursue options for returning the study intervention to the labeled storage conditions, 
as soon as possible. Once an excursion is identified, the study intervention must be 
quarantined and not used until [COMPANY_007] provides permission to use the study intervention. Specific details regarding the excursion definition and information toreport for each excursion will be provided to the site in the PCRU site procedures.
5. Any storage conditions stated in the SRSD will be superseded by [CONTACT_78254].
6. Study interventions should be stored in their original containers.090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 437. The investigator, institution, head of the medical institution (where applicable), or 
authorized site staff is responsible for study intervention accountability, reconciliation, and record maintenance (ie, receipt, reconciliation, and final disposition records), such as the IPAL or sponsor-approved equivalent. All study interventions will be accounted for using a study intervention accountability form/record.
8. Further guidance and information for the final disposition of unused study 
interventions are provided in the PCRU’s site procedures. All destruction must be adequately documented. If destruction is authorized to take place at the investigator site, the investigator must ensure that the materials are destroyed in compliance with applicable environmental regulations, institutional policy, and any special instructions provided by [CONTACT_4618].
Upon identification of a product complaint, notify the sponsor within 1 business day of 
discovery.
6.2.1. Preparation and Dispensing
Within this protocol, preparation refers to the investigator site activities performed to make 
the study intervention ready for administration or dispensing to the participant by [CONTACT_3436]. Dispensing is defined as the provision of study intervention, concomitant treatments, and accompanying information by [CONTACT_22806](s) to a healthcare provider, participant, in accordance with this protocol. Local health authority regulations or investigator site guidelines may use alternative terms for these activities.
PF-[ADDRESS_415396]. Prepared doses will be provided in unit dose containers and labeled in accordance with [COMPANY_007] regulations and the investigator site’s labeling requirements.
PF-[ADDRESS_415397]. Blinded study intervention will be administered in a blinded fashion to the participant. 
6.3. Assignment to Study Intervention
The investigator will assign participant numbers to the participants as they are screened for 
the study. [COMPANY_007] will provide a randomization schedule to the investigator and, in accordance 
with the randomization numbers, the participant will receive the study treatment regimen assigned to the corresponding randomization number.
6.4. Blinding
This is a double-blind (sponsor-unblinded) study. 
6.4.1. Blinding of Participants
Participants will be blinded to their assigned study intervention.090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 446.4.2. Blinding of Site Personnel
Investigators and other site staff will be blinded to participants’ assigned study intervention. 
Participants will be assigned to receive study intervention according to the assigned treatment 
group from the randomization scheme. Investigators will remain blinded to each participant’s assigned study intervention throughout the course of the study. 
In order to maintain this blind, an otherwise uninvolved third party will be responsible for the 
preparation and dispensing of all study intervention and will endeavor to ensure that there are no differences in time taken to dispense or visual presentation, following randomization or dispensing. This third party will instruct the participant to avoid discussing the taste, dosing frequency, or packaging of the study intervention with the investigator. 
In the event of a Quality Assurance audit, the auditor(s) will be allowed access to unblinded 
study intervention records at the site(s) to verify that randomization/dispensing has been done accurately.
PCRU pharmacy staff responsible for preparing all study interventions will be unblinded. 
PCRU site staff providing technical system support to pharmacy staff and supporting blinded laboratory data processes will be unblinded. These site staff providing system support will not be involved in any data collection or clinic floor activities.
6.4.3. Blinding of the Sponsor
As this is a sponsor-open study, the sponsor may conduct unblinded reviews of the data 
during the course of the study for the purpose of safety assessment, facilitating dose-escalation decisions, facilitating PK modeling, and/or supporting clinical development.Individual participant-level unblinded data will be reviewed by a designated limited number of sponsor personnel.
6.4.4. Sensitive Clinical Data 
Sensitive clinical data are data collected in this study that have the potential to unblind a 
participant’s treatment assignment. Access to sensitive clinical data will be restricted to authorized individuals until the study has been unblinded. The following data variables are considered sensitive clinical data:
!Study intervention assignments (PF-06954522 or placebo);
!Individual PF-06954522 PK data.
6.4.5. Breaking the Blind 
The method for breaking the blind in this study will be manual. In case of an emergency, the 
investigator has the sole responsibility for determining if unblinding of a participant’streatment assignment is warranted. Participant safety must always be the first consideration in making such a determination. If the investigator decides that unblinding is warranted, the investigator should make every effort to contact [CONTACT_336265] 090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 45unblinding a participant’s treatment assignment unless this could delay further management
of the participant. If a participant’s treatment assignment is unblinded, the sponsor must be notified within [ADDRESS_415398] be fully documented and entered on the CRF.
Blood specimens will be obtained from all participants for PK analysis to maintain the study 
blind at the investigator site. Only the investigator site staff and blinded study monitor, if assigned, will be blinded to study treatment. Other [COMPANY_007] personnel will be unblinded to participant treatments in order to permit real-time interpretation of the safety and PK data; and provide information necessary to potentially alter the dose escalation- sequence. The blinded study monitor, if assigned, will remain blinded to treatment until all monitoring for the study has been completed. Specimens from participants randomized to placebo will not be routinely analyzed. To minimize the potential for bias, treatment randomization information will be kept confidential by [CONTACT_336266].
6.5. Study Intervention Compliance
When the individual dose for a participant is prepared from a bulk supply, the preparation of 
the dose will be confirmed by a second qualified member of the study site staff.
When participants are dosed at the site, they will receive study intervention directly from the 
investigator or designee, under medical supervision. The date and time of each dose administered in the clinic will be recorded in the source documents and recorded in the CRF. The dose of study intervention and study participant identification will be confirmed at the time of dosing by a member of the study site staff other than the person administering the study intervention. Study site personnel will examine each participant’s mouth to ensure that the study intervention was ingested.
6.6. Dose Modification
The decision to proceed to the next dose level of PF-06954522 (either an increase, decrease, 
or repeat of a previous dose level) will be made by [CONTACT_336267], tolerability, and preliminary PK data obtained at the prior dose level. At least 8 and 6 participants (including at least 1 placebo participant) must complete the prior 
dose level in Cohort [ADDRESS_415399]-dose of the current period will be reviewed. Cumulative safety and tolerability from all previous periods will also be reviewed.
The dosing schedule may also be adjusted to expand a dosing cohort to further evaluate 
safety, tolerability, and/or PK findings at a given dose level or to add cohorts to evaluate additional dose levels or repeat dose levels. The study procedures for these additional participant(s)/cohort(s) will be the same as that described for other study participants/cohortsunless otherwise indicated.090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
P F -0 6 9 5 4 5 2 2 
Pr ot oc ol C4 0 0 1 0 0 1 
Fi nal Pr ot oc ol, 1 7 J ul y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol T e m plate ( 1 4 A pril 2 0 2 3) 
Pa ge [ADDRESS_415400] o p pe d if it is deter mi ne d t hat t he li mits of safet y  
a n d/ or t olera bilit y  ha ve bee n reac he d. T his decisi o n will be ma de after a disc ussi o n ta kes 
place bet wee n t he s p o ns or st u d y  tea m a n d t he i n vesti gat or. T he s p o ns or st u d y  tea m ma y  n ot 
o verr ule t he i n vesti gat or’s decisi o n t o st o p d ose escalati o n. If d ose escalati o n is st o p pe d 
beca use of a n y of t hese criteria, a d diti o nal c o h orts ma y recei ve t he sa me or l o wer d oses of 
t he st u d y  i nter ve nti o n .
T he d ose escalati o n will be ter mi nate d base d o n t he f oll o wi n g criteria: 
If 5 0 % or m ore of t he partici pa nt s recei vi n g acti ve dr u g at a gi ve n d ose le vel ( b ut n ot 
partici pa nt s recei vi n g place b o) de vel o p si milar cli nicall y  si g nifica nt la b orat or y , E C G, 
or vital si g n a b n or malities, i n t he sa me or ga n class, i n dicati n g d ose -li miti n g 
i nt olera nce .
Se vere n o nseri o us A Es, c o nsi dere d as, at least, p ossi bl y  relate d t o st u d y  i nter ve nti o n 
a d mi nistrati o n, i n 2 partici pa nts at a gi ve n d ose le vel ( b ut n ot partici pa nts recei vi n g 
place b o), i n de pe n de nt of wit hi n or n ot wit hi n t he sa me s y ste m or ga n class, i n dicati n g 
d ose -li miti n g i nt olera nce .
D osi n g will be pa use d f or a n y S A E t hat occ urs i n a partici pa nt recei vi n g acti ve 
treat me nt u ntil ca usalit y  is f ull y  assesse d b y  t he PI a n d s p o ns or. D osi n g ma y  r e s u me 
if t he S A E is deter mi ne d t o be n ot dr u g-relate d b y t he PI  a n d s p o ns or. If t he S A E is 
deter mi ne d t o be eit her dr u g-relate d or u n k n o w n, eit her d osi n g will cease or t he S A E 
will be e val uate d b y t he s p o ns or’s pr ot oc ol re vie w c o m mittee ( or si milar re vie w 
gr o u p), w hic h is i n de pe n de nt of t he st u d y  tea m a n d i n vesti gat ors. If t he pr ot oc ol 
re vie w c o m mittee deter mi nes t hat d osi n g ma y  res u me, a pla n t hat miti gates ris ks t o 
partici pa nt s wit h t he res u m pti o n of d osi n g will be i m ple me nte d. S uc h a pla n c o ul d 
i ncl u de a re visi o n of i ncl usi o n/e xcl usi o n criteria, re peati n g or re d uci n g t he d ose, or 
a d di n g a p pr o priate safet y m o nit ori n g. 
It is deter mi ne d t hat t he li mit of safet y  a n d/ or t olera bilit y  has bee n reac he d. T his 
decisi o n will be ma de f oll o wi n g disc ussi o ns bet wee n t he st u d y  tea m a n d t he 
i n vesti gat or .
Ot her fi n di n gs t hat, at t he discreti o n of t he st u d y t ea m a n d i n vesti gat or, i n dicate t hat 
d ose escalati o n s h o ul d be halte d .
If, at a n y d ose le vel, t he a vera ge e x p os ure reac hes or e xcee ds t he P K st o p pi n g li mits : 
. 
If, base d o n t he o bser ve d data, t he gr o u p mea n C ma x or A U C ( base d o n t otal plas ma 
c o nce ntrati o n) of t he ne xt pla n ne d d ose is pr ojecte d t o e xcee d t he escalati o n li mits, 
t hat d ose will n ot be e x pl ore d. M o difi e d d oses ma y  be e x pl ore d if t he y  are n ot 
e x pecte d t o e xcee d P K st o p pi n g criteria. 0 9 0 1 7 7 e 1 9 e 0f 3 af c\ A p pr o v e d\ A p pr o v e d O n: 1 9- J ul- 2 0 2 3 0 1: 5 5 ( G M T) C CI 
P F -0 6 9 5 4 5 2 2 
Pr ot oc ol C4 0 0 1 0 0 1 
Fi nal Pr ot oc ol, 1 7 J ul y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol T e m plate ( 1 4 A pril 2 0 2 3) 
Pa ge 4 7 T he hi g hest d ose e val uate d i n t his st u d y  will n ot e xcee d   m g. 
Pr o gressi o n t o t he ne xt d ose will occ ur if t he last d ose was well t olerate d a n d after 
satisfact or y  re vie w of t he a vaila ble safet y a n d P K data. 
6. 7. C o nti n ue d Access t o St u d y I nter ve nti o n After t he E n d of t he St u d y 
N o st u d y i nter ve nti o n will be pr o vi de d t o partici pa nts at t he e n d of t heir st u d y  partici pati o n. 
6. 8. Tre at me nt of O ver d ose 
F or t his st u d y , a n y  d ose of P F - [ADDRESS_415401] o p pi n g li mit of , (see 
Secti o n 6. 6. 1 ) wit hi n a 2 4 -h o ur ti me peri o d will be c o nsi dere d a n o ver d ose. 
T here is n o s pecific treat me nt f or a n o ver d ose. 
I n t he e ve nt of a n o ver d ose, t he i n vesti gat or/treati n g p h ys icia n s h o ul d: 
1. C o ntact t he st u d y  me dical m o nit or wit hi n 2 4 h o urs. 
2. Cl osel y  m o nit or t he partici pa nt f or a n y AEs/ S A Es a n d la b orat or y  a b n or malities as 
me dicall y  a p pr o priate a n d f oll o w u p u ntil res ol uti o n , sta bilizati o n, t he e ve nt is 
ot her wise e x plai ne d, or t he partici pa nt is l ost t o f oll o w -u p (as defi ne d i n Secti o n 7. 3 ). 
3. D oc u me nt t he q ua ntit y of t he e xcess d ose as well as t he d urati o n of t he o ver d ose i n 
t he C R F. 
4. O ver d ose is re p orta ble t o [COMPANY_007] Safet y  o nl y w he n ass oci ate d wit h a n S A E. 
5. O btai n a bl o o d sa m ple f or P K a nal ys is wit hi n 2da ys fr o m t he date of t he last d ose of 
st u d y  i nter ve nti o n if re q ueste d b y  t he st u d y  me dical m o nit or ( deter mi ne d o n a 
case -b y -case basis). 
Decisi o ns re gar di n g d ose i nterr u pti o ns or m o dificati o ns will be ma de b y  t he i n vesti gat or i n 
c o ns ultati o n wit h t he st u d y  me dical m o nit or as nee de d base d o n t he cli nical e val uati o n of t he 
partici pa nt. 
6. 9. Pri or a n d C o nc o mit a nt T her a p y 
Use of prescri pti o n or n o n prescri pti o n dr u gs a n d dietar y  a n d her bal s u p ple me nts are 
pr o hi bite d wit hi n 7 da y s or 5 half -li ves ( w hic he ver is l o n ger) pri or t o t he first d ose of st u d y  
i nter ve nti o n wit h t he e xce pti o n of  w hic h 
are pr o hi b ite d wit hi n [ADDRESS_415402] u d y i nter ve nti o n (see 
A p pe n di x 9 ). 
Li mite d use of n o n prescri pti o n me dicati o ns t hat are n ot belie ve d t o affect partici pa nt safet y  
or t he o verall r es ults of t he st u d y  ma y  be per mitte d o n a case -b y -case basis f oll o wi n g 
a p pr o val b y t he s p o ns or .Aceta mi n o p he n/ paraceta m ol ma y  be use d at d oses of ≤ 1 g/ da y .0 9 0 1 7 7 e 1 9 e 0f 3 af c\ A p pr o v e d\ A p pr o v e d O n: 1 9- J ul- 2 0 2 3 0 1: 5 5 ( G M T) C CI 
C CI C CI 
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 48Females taking hormone replacement therapy may be eligible to participate in this study if 
they are willing to discontinue therapy at least [ADDRESS_415403] dose of study intervention will be documented as concomitant treatments.
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL
7.1. Discontinuation of Study InterventionIt may be necessary for a participant to permanently discontinue study intervention. Reasons 
for permanent discontinuation of study intervention include the following: AEs or other (administrative) reasons.
Discontinuation of study intervention does not represent withdrawal from the study. If study 
intervention is permanently discontinued, the participant should remain in the study to be evaluated for ongoing AEs. See the SoA for data to be collected at the time of 
discontinuation of study intervention and follow-up for any further evaluations that need to be completed.
In the event of discontinuation of study intervention, it must be documented on the 
appropriate CRF/in the medical records whether the participant is discontinuing further receipt of study intervention or also from study procedures, further study follow-up, and/or future collection of additional information.
7.1.1. Potential Cases of Acute Kidney InjuryParticipants exposed to IMP demonstrating transient or sustained increase in Screat (with 
decrease in Screat-based eGFR or eCrCl) require expedited evaluation to differentiate AKI from DICI. DICI is defined as transporter-mediated effect related to altered renal tubular creatinine handling without histological injury.
AKI may be due to one or more types of injury, including DIKI. Differentiation of DIKI 
from other causes of AKI and from DICI may require clinical, radiographic, histopathologic, 
and laboratory assessments, as well as nephrology consultation.
Follow-up AssessmentsThe participant should return to the site for evaluation as soon as possible, preferably within 
48 hours of awareness of the abnormal results. 090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 49Evaluation should include physical examination, laboratory tests, detailed medical and 
surgical history, review of all medications (including recreational drugs and supplements [herbal]), family history, sexual history, travel history, blood transfusion, and potential occupational exposure to chemicals. 
Laboratory assessments should include simultaneous serum cystatin C (Scys) and serum 
creatinine (Screat) tests. Estimates of eGFR, eCrCl and Screat-based eGFR and combined Screat-Scys-based eGFR should also be derived using the appropriate equation described in Appendix [ADDRESS_415404]-renal obstruction. 
Differentiating Acute Kidney Injury from DICIA confirmed Screat increase is defined as:(i) ≥0.3 mg/dL ( ≥26.5 μmol/L) within 48 hours OR 
(ii) confirmed Screat increase ≥1.5 times baseline (known or suspected to have occurred 
within the prior 7 days). 
Based on the assessments performed, suspected AKI (including DIKI) may be differentiated 
from DICI as follows.
Adult participants
AKI (including DIKI)
Any one of the belowDICI
Scys & Screat Simultaneous, confirmed serum cystatin 
C (Scys) increase and confirmed Screat increase Confirmed Screat increase without 
confirmed increase in reflex Scys AND Confirmed Screat-based eGFR decrease without confirmed combined Screat-Scys-based eGFR decrease.
eGFR Decrease in Screat-based eGFR and 
combined Screat-Scys-based eGFR (when 
available)
Albuminuria or 
proteinuriaConfirmed albuminuria increase (see 
Appendix 7 for Grades A1 to A3 
quantitation)
Urine volume Urine volume <0.5 mL/kg/h for 
6 consecutive hours090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 50Regardless of the presence or absence of increase in Screat, DIKI and other causes of AKI 
may be suspected if either there is (i) new-onset or worsening albuminuria or proteinuria are detected.
All confirmed cases of clinically relevant decrease in kidney function should be considered 
potential cases of DIKI if no other reason for the kidney function abnormalities has been found.
7.1.2. Liver Injury
A participant who meets any of the following will be withdrawn from the study 
intervention.[ 16]
!ALT or AST >8 × ULN;
!ALT or AST >5 × ULN for more than 2 weeks;
!ALT or AST >3 × ULN and (T bili >2 × ULN or INR >1.5);
!ALT or AST >3 × ULN with the appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%).
See Section 10.6 for Potential Cases of Drug Induced Liver Injury.
7.1.3. ECG Changes
A participant who meets either bulleted criterion based on the average of triplicate ECG 
readings will be withdrawn from the study intervention. 
!QTcF >500 ms.
!Change from baseline: QTcF >60 ms and QTcF >450 ms.
If a clinically significant finding is identified (including, but not limited to, changes from 
baseline in QTcF after enrollment), the investigator or qualified designee will determine if the participant can continue in the study and if any change in participant management is needed. This review of the ECG printed at the time of collection must be documented. Any new clinically relevant finding should be reported as an AE.
7.1.4. COVID-19 If a participant has COVID-19 during the study, this should be reported as an AE or SAE (as 
appropriate) and appropriate medical intervention provided. Study treatment should continue unless the investigator/treating physician is concerned about the safety of the participant, in which case temporary or permanent discontinuation may be required. 
It is recommended that the investigator discuss temporary or permanent discontinuation of 
study intervention with the study medical monitor. 090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 517.2. Participant Discontinuation/Withdrawal From the Study
A participant may withdraw from the study at any time at their own request. Reasons for 
discontinuation from the study include the following:
!Refused further study procedure;
!Lost to follow-up;
!Death;
!Study terminated by [CONTACT_3211];
!Discretion of the investigator or sponsor for safety or behavioral reasons, or the 
inability of the participant to comply with the protocol required schedule of study 
visits or procedures. 
At the time of discontinuing from the study, if possible, an early discontinuation visit should 
be conducted. See the SoA for assessments to be collected at the time of study 
discontinuation and follow-up and for any further evaluations that need to be completed. 
The early discontinuation visit applies only to participants who are enrolled/randomized and 
then are prematurely withdrawn from the study. Participants should be questioned regarding their reason for withdrawal.
The participant will be permanently discontinued from the study intervention and the study at 
that time.
If a participant withdraws from the study, they may request destruction of any remaining 
samples taken and not tested, and the investigator must document any such requests in the 
site study records and notify the sponsor accordingly.
If the participant withdraws from the study and also withdraws consent (see Section 7.2.[ADDRESS_415405] with them or persons previously authorized by [CONTACT_104140]. Participants should notify the investigator in writing of the decision to withdraw consent from future follow-up, whenever possible. The withdrawal of consent should be explained in detail in the medical records by [CONTACT_093], as to whether the withdrawal is only from further receipt of study intervention or also from study procedures and/or posttreatment study follow-up, and entered on the appropriate CRF page. In the event that vital status (whether 090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 52the participant is alive or dead) is being measured, publicly available information should be 
used to determine vital status only as appropriately directed in accordance with local law.
7.3. Lost to Follow-Up 
A participant will be considered lost to follow-up- if the participant repeatedly fails to return 
for scheduled visits and is unable to be contact[CONTACT_9298].
The following actions must be taken if a participant fails to return to the clinic for a required 
study visit:
!The site must attempt to contact [CONTACT_14315]. Counsel the participant on the importance of maintaining the assigned visit schedule and ascertain whether the participant wishes to and/or should continue in the study;
!Before a participant is deemed lost to follow-up, the investigator or designee must 
make every effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls and, if necessary, a certified letter to the participant’s last known mailing address or local equivalent methods). These contact [CONTACT_13140]’s medical record;
!Should the participant continue to be unreachable, the participant will be considered 
to have withdrawn from the study. 
8. STUDY ASSESSMENTS AND PROCEDURES
8.1. Administrative and Baseline ProceduresThe investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing any study-specific procedures. 
Study procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.
Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for study conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log torecord details of all participants screened and to confirm eligibility or record reasons for screening failure, as applicable.
Participants will be screened within 28 days prior to administration of the study intervention
to confirm that they meet the study population criteria for the study. If the time between screening and dosing exceeds 28 days as a result of unexpected delays (eg, delayed drug shipment), then participants do not require rescreening if the laboratory results obtained prior to first dose administration meet eligibility criteria.090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 53A participant who qualified for this protocol but did not enroll from an earlier cohort/group
may be used in a subsequent cohort/group without rescreening, provided laboratory results obtained prior to the first dose administration meet eligibility criteria for this study. In addition, other clinical assessments or specimen collections, eg, retained research samples, may not need to be repeated, as appropriate.
Every effort should be made to ensure that protocol-required tests and procedures are 
completed as described. However, it is anticipated that from time to time there may be circumstances outside the control of the investigator that make it unfeasible to perform the test. In these cases, the investigator must take all steps necessary to ensure the safety and well-being of the participant. When a protocol-required test cannot be performed, the investigator will document the reason for the missed test and any corrective and preventiveactions that they have taken to ensure that required processes are adhered to as soon as possible. The study team must be informed of these incidents in a timely manner.
Any safety, laboratory or analyte results that have been collected for the purposes of this 
study and could unblind the study will not be reported to investigative sites or other blinded personnel until the study has been unblinded.
If done around the time of a blood draw, ECGs and vital sign assessments (BP and pulse rate) 
should be collected before the blood draw. 
If an IV catheter is utilized for blood sample collections, ECGs and vital sign assessments 
(pulse rate and BP) should be collected prior to the insertion of the catheter.
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact [CONTACT_22819].
The total blood sampling volume for individual participants in Cohorts 1, 2 and 3 of this 
study are approximately 545, 440 and 340 mL, respectively. The actual collection times of blood sampling may change. Additional blood samples may be taken for safety assessmentsat times specified by [CONTACT_4618], provided the total volume taken during the study does not exceed 550 mL during any period of 56 consecutive days.
To prepare for study participation, participants will be instructed on the information in the 
Lifestyle Considerations and Concomitant Therapy sections of the protocol.
8.2. Efficacy Assessments
Efficacy parameters are not evaluated in this study. 
8.3. Safety Assessments
Planned time points for all safety assessments are provided in the SoA. Unscheduled safety 
measurements may be obtained at any time during the study to assess any perceived safety issues.090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 548.3.1. Physical Examinations
A complete physical examination will include, at a minimum, head, ears, eyes, nose, mouth, 
skin, heart and lung examinations, lymph nodes, and gastrointestinal, musculoskeletal, and neurological systems. 
A brief physical examination will include, at a minimum, assessments of general appearance, 
the respi[INVESTIGATOR_110251], and participant-reported symptoms.
Physical examinations may be conducted by a physician, trained physician’s assistant, or 
nurse practitioner as acceptable according to local regulation. 
Height and weight will also be measured and recorded as per the SoA. For measuring weight, 
a scale with appropriate range and resolution is used and must be placed on a stable, flat surface. Participants must remove shoes, bulky layers of clothing, and jackets so that only light clothing remains. They must also remove the contents of their pockets and remain still during measurement of weight. 
Physical examination findings collected during the study will be considered source record 
and will not be required to be reported, unless otherwise noted. Any untoward physical examination findings that are identified during the active collection period and meet thedefinition of an AE or SAE ( Appendix 3 ) must be reported according to the processes in 
Sections 8.4.1 to 8.4.3 .
8.3.2. Vital Signs
[IP_ADDRESS]. Blood Pressure and Pulse RateSupi[INVESTIGATOR_78235]’s arm supported at the level of the heart, and 
recorded to the nearest mm Hg after approximately [ADDRESS_415406]. The same arm (preferably the dominant arm) will be used throughout the study. Participants should be instructed not to speak during measurements. When triplicate measurements of supi[INVESTIGATOR_336247], measurements should be collected 2-4 minutes apart.
The same properly sized and calibrated BP cuff will be used to measure BP each time. The 
use of an automated device for measuring BP and pulse rate is acceptable; however, when done manually, pulse rate will be measured in the brachial/radial artery for at least [ADDRESS_415407] vital sign findings that are identified during the active collection period and 
meet the definition of an AE or SAE ( Appendix 3 ) must be reported according to the 
processes in Sections 8.4.1 to 8.4.3 .090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page [IP_ADDRESS]. Respi[INVESTIGATOR_336248] [ADDRESS_415408] and before BP measurement.
[IP_ADDRESS]. Body Temperature
Body temperature will be measured orally. No eating, drinking, or smoking is allowed for 
[ADDRESS_415409] 5 minutes in a supi[INVESTIGATOR_2547]. 
Triplicate 12-lead ECGs will be obtained approximately 2 to 4 minutes apart; the average of 
the triplicate ECG measurements collected at -1.0, -0.5, and 0 hours pre-dose on Day 1 of each period will serve as each participant’s baseline QTcF value. 
To ensure safety of the participants, a qualified individual at the investigator site will make 
comparisons to baseline measurements. Additional ECG monitoring will occur if a) the mean value from the triplicate measurements for any postdose QTcF interval is increased by ≥60 ms from the baseline andis >450 ms; or b) an absolute QT value is ≥[ADDRESS_415410] hourly until QTcF values from 2 successive ECGs fall below the threshold value that triggered the repeat measurement.
For single ECG collection, additional ECG monitoring will occur if a) a postdose QTcF
interval is increased by ≥60 ms from the baseline andis >450 ms; or b) an absolute QT value 
is ≥[ADDRESS_415411] hourly until QTc values from 2 successive ECGs fall below the threshold value that triggered the repeat measurement.
If a) a postdose QTcF interval remains ≥60 ms from the baseline andis >450 ms; or b) an 
absolute QT value is ≥500 ms for any scheduled ECG for greater than 4 hours (or sooner, at 
the discretion of the investigator); or c) QTcF value get progressively longer, the participantshould undergo continuous ECG monitoring. A cardiologist should be consulted if QTcFvalues do not return to less than the criteria listed above after 8 hours of monitoring (or sooner, at the discretion of the investigator).
In some cases, it may be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality. It is important that leads be placed in the 090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 56same positions each time in order to achieve precise ECG recordings. If a machine-read QTc 
value is prolonged, as defined above, repeat measurements may not be necessary if a qualified medical provider’s interpretation determines that the QTcF values are in the acceptable range.
ECG values of potential clinical concern are listed in Appendix 8 .
[IP_ADDRESS]. Continuous Cardiac Monitoring by [CONTACT_336268]. The time, duration, and description of the clinically significant event will be recorded in the CRF. In addition, a printed record of the tracing(s) of the clinically significant rhythm(s) will be made and retained with other source documents.
Telemetry should be collected using a centralized system that also allows for the storage and 
advanced analysis of all recorded data in order to preserve important events for future evaluations. Holter monitoring should not be used in parallel with continuous telemetry, unless it is the only means of data storage available at the investigator site, or verifiable arrhythmia quantification is required. To establish a baseline, telemetry should be recorded for at least [ADDRESS_415412] findings are those that are not associated with 
the underlying disease, unless judged by [CONTACT_78259]’s condition.
All laboratory tests with values considered clinically significant and abnormal during 
participation in the study or within [ADDRESS_415413] dose of study intervention should be repeated until the values return to normal or baseline or are no longer considered clinically significant by [CONTACT_219883].
If such values do not return to normal/baseline within a period of time judged reasonable by 
[CONTACT_093], the etiology should be identified and the sponsor notified.090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 57See Appendix [ADDRESS_415414] be negative for participants to receive study intervention. 
8.4. Adverse Events, Serious Adverse Events, and Other Safety Reporting
The definitions of an AE and an SAE can be found in Appendix 3 .
AEs may arise from symptoms or other complaints reported to the investigator by [CONTACT_2416] (or, when appropriate, by a caregiver, surrogate, or the participant’s legally authorized representative), or they may arise from clinical findings of the investigator or other healthcare providers (clinical signs, test results, etc).
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue and obtain adequate information both to determine the outcome and to assess whether the event meets the criteria for classification as an SAE or caused the participant to discontinue the study intervention (see Section 7.1 ). 
During the active collection period as described in Section 8.4.1 , each participant will be 
questioned about the occurrence of AEs in a nonleading manner.
In addition, the investigator may be requested by [CONTACT_22835]-up 
information in an expedited fashion.
8.4.1. Time Period and Frequency for Collecting AE and SAE Information
The time period for actively eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, which is obtained before undergoing any study-related procedure and/or receiving study intervention), through and including a minimum of [ADDRESS_415415] administration of the study intervention.
Follow-up by [CONTACT_185615] a level acceptable to the investigator.
When a clinically important AE remains ongoing at the end of the active collection period, 
follow-up by [CONTACT_336269] a level acceptable to the investigator and [COMPANY_007] concurs with that assessment.
For participants who are screen failures, the active collection period ends when screen failure 
status is determined.090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 58If the participant withdraws from the study and also withdraws consent for the collection of 
future information, the active collection period ends when consent is withdrawn.
If a participant permanently discontinues or temporarily discontinues study intervention 
because of an AE or SAE, the AE or SAE must be recorded on the CRF and the SAE reported using the CT SAE Report Form.
Investigators are not obligated to actively seek information on AEs or SAEs after the 
participant has concluded study participation. However, if the investigator learns of any SAE, including a death, at any time after a participant has concluded study participation, and theyconsider the event to be reasonably related to the study intervention, the investigator must promptly report the SAE to [COMPANY_007] using the CT SAE Report Form.
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participant during the active collection period as described in 
Section 8.4.[ADDRESS_415416] SAE Report Form immediately upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in Appendix 3 . The investigator will submit any updated SAE data to the sponsor within 
24 hours of its being available.
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which begins after obtaining informed consent as described in Section 8.4.[ADDRESS_415417] to the CRF 
requirements as described in Section 5.4 .
8.4.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 .
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about AE occurrences.090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 598.4.3. Follow-up of AEs and SAEs
After the initial AE or SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and obtain adequate information until resolution, stabilization, the event is otherwise explained, or the participant is lost to follow-up (as defined in Section 7.3 ).
In general, follow-up- information will include a description of the event in sufficient detail 
to allow for a complete medical assessment of the case and independent determination of possible causality. Any information relevant to the event, such as concomitant medications and illnesses, must be provided. In the case of a participant death, a summary of available autopsy findings must be submitted as soon as possible to [COMPANY_007] Safety. 
Further information on follow-up procedures is provided in Appendix [ADDRESS_415418] the safety of participants and the safety of a study intervention under clinical investigation are met.
The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The sponsor will comply with country-specific regulatory requirements relating to safety reporting to the regulatory authority, IRBs/ECs, and investigators.
Investigator safety reports must be prepared for S[LOCATION_003]Rs according to local regulatory 
requirements and sponsor policy and forwarded to investigators as necessary.
An investigator who receives S[LOCATION_003]Rs or other specific safety information (eg, summary or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the study and will notify the IRB/EC, if appropriate according to local requirements.
8.4.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, and 
Occupational Exposure
Environmental exposure occurs when a person not enrolled in the study as a participant 
receives unplanned direct contact [CONTACT_273478]. Such exposure may or may not lead to the occurrence of an AE or SAE. Persons at risk for environmental exposure include healthcare providers, family members, and others who may be exposed. An environmental exposure may include EDP, EDB, and occupational exposure.
Any such exposures to the study intervention under study are reportable to [COMPANY_007] Safety 
within 24 hours of investigator awareness.
[IP_ADDRESS]. Exposure During Pregnancy
An EDP occurs if:090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 60!A female participant is found to be pregnant while receiving or after discontinuing 
study intervention .
!A male participant who is receiving or has discontinued study intervention
inseminates a female partner.
!A female nonparticipant is found to be pregnant while being exposed or having been 
exposed to study intervention because of environmental exposure. Below are examples of environmental EDP:  
!A female family member or healthcare provider reports that she is pregnant after 
having been exposed to the study intervention by [CONTACT_78262], inhalation, or skin contact.
!A male family member or healthcare provider who has been exposed to the study 
intervention by [CONTACT_78262], inhalation, or skin contact [CONTACT_336270].
The investigator must report EDP to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted should include the anticipated date of delivery (see below for information related to termination of pregnancy). 
!If EDP occurs in a participant/participant’s partner, the investigator must report this 
information to [COMPANY_007] Safety using the CT SAE Report Form and EDP Supplemental Form regardless of whether an SAE has occurred. Details of the pregnancy will be collected after the start of study intervention and until [ADDRESS_415419] dose of study intervention.
!If EDP occurs in the setting of environmental exposure, the investigator must report 
information to [COMPANY_007] Safety using the CT SAE Report Form and EDP Supplemental Form. Since the exposure information does not pertain to the participant enrolled in the study, the information is not recorded on a CRF; however, a copy of the completed report is maintained in the investigator site file.
Follow-up is conducted to obtain general information on the pregnancy and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy until completion (or until pregnancy termination) and notify [COMPANY_007] Safety of the outcome as a follow-up to the initial report. In the case of a live birth, the structural integrity of the neonate can be assessed at the time of birth. In the event of a termination, the reason(s) for termination should be specified and, if clinically possible, the structural integrity of the terminated fetus should be assessed by [CONTACT_4692] (unless pre-procedure test findings are conclusive for a congenital anomaly and the findings are reported).
Abnormal pregnancy outcomes are considered SAEs. If the outcome of the pregnancy meets 
the criteria for an SAE (ie, ectopic pregnancy, spontaneous abortion, intrauterine fetal 090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 61demise, neonatal death, or congenital anomaly in a live-born baby, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures for reporting SAEs. Additional information about pregnancy outcomes that are reported to [COMPANY_007] Safety as SAEs follows: 
!Spontaneous abortion including miscarriage and missed abortion should be reported 
as an SAE;
!Neonatal deaths that occur within [ADDRESS_415420] 
to causality, as SAEs. In addition, infant deaths after 1 month should be reported as SAEs when the investigator assesses the infant death as related or possibly related to exposure to the study intervention. 
Additional information regarding the EDP may be requested by [CONTACT_456]. Further 
follow-up of birth outcomes will be handled on a case-by-case basis (eg, follow-up on preterm infants to identify developmental delays). In the case of paternal exposure, the investigator will provide the participant with the Pregnant Partner Release of Information Form to deliver to his partner. The investigator must document in the source documents that the participant was given the Pregnant Partner Release of Information Form to provide to his partner.
[IP_ADDRESS]. Exposure During Breastfeeding
An EDB occurs if: 
!A female participant is found to be breastfeeding while receiving or after 
discontinuing study intervention.
!A female nonparticipant is found to be breastfeeding while being exposed or having 
been exposed to study intervention (ie, environmental exposure). An example of environmental EDB is a female family member or healthcare provider who reports that she is breastfeeding after having been exposed to the study intervention by [CONTACT_78262], inhalation, or skin contact. 
The investigator must report EDB to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The information must be reported using the CT SAE Report Form. When EDB occurs in the setting of environmental exposure, the exposure information does not pertain to the participant enrolled in the study , so the 
information is not recorded on a CRF. However, a copy of the completed report is maintained in the investigator site file.
An EDB report is not created when a [COMPANY_007] drug specifically approved for use in 
breastfeeding women (eg, vitamins) is administered in accordance with authorized use. However, if the infant experiences an SAE associated with such a drug, the SAE is reported together with the EDB.090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page [IP_ADDRESS]. Occupational Exposure
The investigator must report any instance of occupational exposure to [COMPANY_007] Safety within 24 
hours of the investigator’s awareness using the CT SAE Report Form regardless of whether there is an associated SAE. Since the information about the occupational exposure does not pertain to a participant enrolled in the study, the information is not recorded on a CRF; however, a copy of the completed report is maintained in the investigator site file.
8.4.6. Cardiovascular and Death Events
Not applicable.
8.4.7. Disease-Related Events and/or Disease-Related Outcomes Not Qualifying as AEs 
or SAEs
Not applicable.
8.4.8. Adverse Events of Special Interest
Not applicable.
[IP_ADDRESS]. Lack of Efficacy
This section is not applicable because efficacy is not expected in the study population.
8.4.9. Medical Device Deficiencies
Not Applicable.
8.4.10. Medication Errors
Medication errors may result from the administration or consumption of the study 
intervention by [CONTACT_19995], or at the wrong time, or at the wrong dosage strength.
Medication errors are recorded and reported as follows:
Recorded on the 
Medication Error Page 
of the CRFRecorded on the 
Adverse Event Page 
of the CRFReported on the CT SAE 
Report Form to [COMPANY_007] 
Safety Within 24 Hours of 
Awareness
All (regardless of whether 
associated with an AE)Any AE or SAE associated 
with the medication errorOnly if associated with an 
SAE
Medication errors include:
!Medication errors involving participant exposure to the study intervention;
!Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study participant.090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 63!The administration of expi[INVESTIGATOR_336249];
!The administration of an incorrect study intervention;
!The administration of an incorrect dosage;
!The administration of study intervention that has undergone temperature excursion 
from the specified storage range, unless it is determined by [CONTACT_336271].
Whether or not the medication error is accompanied by [CONTACT_1149], as determined by [CONTACT_1275], such medication errors occurring to a study participant are recorded on the medication error page of the CRF, which is a specific version of the AE page and, if applicable, any associated serious and nonserious AE(s), are recorded on the AE page of the CRF.
In the event of a medication dosing error, the sponsor should be notified within [ADDRESS_415421] SAE Report 
Form only when associated with an SAE.
8.5. Pharmacokinetics 
Blood samples of approximately 4 mL to provide approximately 1.6 mL of plasma, will be 
collected for measurement of plasma concentrations of PF-06954522 as specified in the SoA. 
Instructions for the collection and handling of biological samples will be provided in the laboratory manual or by [CONTACT_456]. The actual times may change but the actual date and time (24-hour clock time) of each sample will be recorded.
All efforts will be made to obtain the samples at the exact nominal time relative to dosing.
Collection of samples up to and including 10 hours after dose administration that areobtained within 10% of the nominal time relative to dosing (eg, within 6 minutes of a 60-minute sample) will not be captured as a protocol deviation, as long as the exact time of the collection is noted on the source document and the CRF. Collection of samples more than 10 hours after dose administration that are obtained ≤[ADDRESS_415422] time of the collection is noted on the source document and the CRF. This protocol deviation window does not apply to samples to be collected more than 10 hours after dose administration at outpatient/follow-up visits with visit windows.
Samples will be used to evaluate the PK of PF-06954522. Samples collected for analyses of 
PF-06954522 plasma concentration may also be used to evaluate safety or efficacy aspects related to concerns arising during or after the study, for metabolite identification and/or evaluation of the bioanalytical method, or for other internal exploratory purposes. The exploratory results may not be reported in the CSR.090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
P F -0 6 9 5 4 5 2 2 
Pr ot oc ol C4 0 0 1 0 0 1 
Fi nal Pr ot oc ol, 1 7 J ul y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol T e m plate ( 1 4 A pril 2 0 2 3) 
Pa ge [ADDRESS_415423] be pr ocesse d a n d s hi p pe d as i n dicate d i n t he i nstr ucti o ns pr o vi de d t o 
t he i n vesti gat or site t o mai ntai n sa m ple i nte grit y .A n y  de viati o ns fr o m t he P K sa m ple 
ha n dli n g pr oce d ure ( e g , sa m ple c ollecti o n a n d pr ocessi n g ste ps, i nteri m st ora ge or s hi p pi n g 
c o n diti o ns), i ncl u di n g a n y  acti o ns ta ke n, m ust be d oc u me nte d a n d re p orte d t o t he s p o ns or. 
O n a case -b y -case basis, t he s p o ns or ma y  ma ke a deter mi nati o n as t o w het her sa m ple 
inte grit y has bee n c o m pr o mise d. 
Dr u g c o nce ntrati o n i nf or mati o n t hat ma y  u n bli n d t he st u d y  will n ot be re p o rte d t o 
i n vesti gat or sites or bli n de d pers o n nel u ntil t he st u d y  has bee n u n bli n de d. 
A n y  c ha n ges i n t he ti mi n g or a d diti o n of ti me p oi nts f or a n y  pla n ne d st u d y assess me nts m ust 
be d oc u me nte d a n d a p pr o ve d b y  t he rele va nt st u d y  tea m me m ber a n d t he n arc hi ve d i n t he 
s p o ns or a n d site st u d y  files, b ut will n ot c o nstit ute a pr ot oc ol a me n d me nt . T h e I R B/ E C will 
be i nf or me d of a n y safet y iss ues t hat re q uire alterati o n of t he safet y m o nit ori n g sc he me or 
a me n d me nt of t he I C D. 
8. 6. Ge netics 
8. 6. 1. S pecifie d Ge netics 
S pecifie d g e netic a nal ys es are n ot e val uate d i n t his st u d y .
8. 6. 2. Ret ai ne d Rese arc h S a m ples f or Ge netics 
A4- m L  bl o o d sa m ple o pti mize d f or D N A is olati o n Pre p D 1 will be c ollecte d acc or di n g t o 
t he S o A ,as l ocal re g ulati o ns a n d I R Bs/ E Cs all o w. 
Retai ne d Researc h Sa m ples ma y  be use d f or researc h relate d t o t he st u d y  i nter ve nti o n (s) . 
Ge nes a n d ot her a nal y tes (e g ,pr otei ns, R N A, n o n dr u g meta b olites) ma y  be st u die d usi n g t he 
retai ne d sa m ples. 
See A p pe n di x 5f or inf or mati o n re gar di n g ge netic researc h. Details o n pr ocesses f or 
c oll ecti o n a n d s hi p me nt of t hese sa m ples ca n be f o u n d i n i n t he la b ma n ual a n d ot her 
s u p p orti n g d oc u me ntati o n. 
8. 7. Bi o m ar kers 
8. 7. 1. Pl as m a f or Me as ure me nt of 
Bl o o d sa m ples of a p pr o xi matel y  2 m L , t o pr o vi de a mi ni m u m of a p pr o xi matel y  0. 8 m L 
plas ma, will be c ollecte d i nt o a p pr o priatel y la bele d t u bes c o ntai ni n g K 2E D T A f or 
meas ure me nt of plas ma c o nce ntrati o ns of  at ti mes s pecifie d i n t he S o A . T hese sa m ples 
will be a nal yz e d at t he discreti o n of t he s p o ns or. If a nal ys is of t he  sa m ples i s j u d ge d t o 0 9 0 1 7 7 e 1 9 e 0f 3 af c\ A p pr o v e d\ A p pr o v e d O n: 1 9- J ul- 2 0 2 3 0 1: 5 5 ( G M T) C CI 
C CI 
C CI 
P F -0 6 9 5 4 5 2 2 
Pr ot oc ol C4 0 0 1 0 0 1 
Fi nal Pr ot oc ol, 1 7 J ul y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol T e m plate ( 1 4 A pril 2 0 2 3) 
Pa ge [ADDRESS_415424] ual date a n d 
ti me ( 2 4- h o ur cl oc k ti me) of eac h sa m ple will be rec or de d .
All eff orts will be ma de t o o btai n t he sa m ples at t he e xact n o mi nal ti me relati ve t o d osi n g. 
C ollecti o n of sa m ples u p t o a n d i ncl u di n g 1 0 h o urs after d ose a d mi nistrati o n t hat are 
o btai ne d wit hi n 1 0 % of t he n o mi nal ti me relati ve t o d osi n g (e g, wit hi n 6 mi n utes of a 
6 0- mi n ute sa m ple) will n ot be ca pt ure d as a pr ot oc ol de viati o n, as l o n g as t he e xact ti me of 
t he c ollecti o n is n ote d o n t he s o urce d oc u me nt a n d t he C R F. C ollecti o n of sa m ples m ore t ha n 
1 0 h o urs after d ose a d mi nistrati o n t hat are o btai ne d ≤ [ADDRESS_415425] u d y, f or meta b olite 
i de ntificati o n a n d/ or e val uati o n of t he bi oa nal yt ical met h o d, or f or ot her i nter nal e x pl orat or y  
p ur p oses. T he e x pl orat or y res ults ma y  n ot be re p orte d i n t he C S R. 
Ge netic a nal ys es will n ot be perf or me d o n t hese plas ma sa m ples u nless c o nse nt f or t his was 
i ncl u de d i n t he i nf or me d c o nse nt. Partici pa nt c o nfi de ntialit y  will be mai ntai ne d. 
Sa m ples c ollecte d f or meas ure me nt of plas ma c o nce ntrati o ns of  will be a nal yz e d usi n g 
a vali date d a na l y tical met h o d i n c o m plia nce wit h a p plica ble S O Ps. 
T he sa m ples m ust be pr ocesse d a n d s hi p pe d as i n dicate d i n t he i nstr ucti o ns pr o vi de d t o 
t he i n vesti gat or site t o mai ntai n sa m ple i nte grit y . A n y  de viati o ns fr o m t he sa m ple ha n dli n g 
pr oce d ure (e g, sa m ple c ollecti o n a n d pr ocessi n g ste ps, i nteri m st ora ge or s hi p pi n g 
c o n diti o ns), i ncl u di n g a n y acti o ns ta ke n, m ust be d oc u me nte d a n d re p orte d t o t he s p o ns or. 
O n a case -b y -case basis, t he s p o ns or ma y  ma ke a deter mi nati o n as t o w het her sa m ple 
i nte grit y has bee n c o m pr o mise d. 
c o nce ntrati o n i nf or mati o n t hat ma y  u n bli n d t he st u d y  will n ot be re p orte d t o 
i n vesti gat or sites or bli n de d pers o n nel u ntil t he st u d y  has bee n u n bli n de d. 
A n y  c ha n ges i n t he ti mi n g or a d diti o n of ti me p oi nts f or a n y  pla n ne d st u d y assess me nts m ust 
be d oc u me nte d a n d a p pr o ve d b y  t he rele va nt st u d y  tea m me m ber a n d t he n arc hi ve d i n t he 
s p o ns or a n d site st u d y  files, b ut will n ot c o nstit ute a pr ot oc ol a me n d me nt. T he I R B/ E C will 
be i nf or me d of a n y safet y iss ues t hat re q uire alterati o n of t he safet y m o nit ori n g sc he me or 
a me n d me nt of t he I C D. 
8. 7. 2. Ret ai ne d Rese arc h S a m ples f or Bi o m ar kers 
T hese Retai ne d Researc h Sa m ples will be c ollecte d i n t his st u d y :0 9 0 1 7 7 e 1 9 e 0f 3 af c\ A p pr o v e d\ A p pr o v e d O n: 1 9- J ul- 2 0 2 3 0 1: 5 5 ( G M T) C CI 
C CI 
C CI 
C CI 
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 66!A 2 mL whole blood Prep B2.5 optimized for serum as outlined in the SoA.
Retained Research Samples will be collected as local regulations and IRB/ECs allow 
according to the SoA. 
Retained Research Samples may be used for research related to the study intervention(s).
Genes and other analytes (eg, proteins, RNA, nondrug metabolites) may be studied using the retained samples. 
See Appendix 5 for information regarding genetic research. Details on processes for 
collection and shipment of these samples can be found in in the lab manual and other supporting documentation. 
8.8. Immunogenicity Assessments
Immunogenicity assessments are not included in this study.
8.9. Health Economics
Health economics/medical resource utilization and health economics parameters are not 
evaluated in this study.
9. STATISTICAL CONSIDERATIONS
Detailed methodology for summary and statistical analyses of the data collected in this study 
is outlined here and further detailed in the SAP, which will be maintained by [CONTACT_456]. The SAP may modify what is outlined in the protocol where appropriate; however, any major modifications of the primary endpoint definitions or their analyses will also be reflected in a protocol amendment.
9.1. Statistical Hypothesis
No formal statistical hypothesis testing will be performed in this study.
9.2. Analysis Sets
For purposes of analysis, the following analysis sets are defined:
Participant Analysis 
SetDescription
Enrolled “Enrolled” means a participant’s, or their legally authorized 
representative’s, agreement to participate in a clinical study following completion of the informed consent process and randomization to study intervention. 
Safety analysis set All participants randomly assigned to study intervention and 
who take at least [ADDRESS_415426] they actually received.090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 67Participant Analysis 
SetDescription
PK Concentration Set All participants randomly assigned to study intervention and 
who receive at least [ADDRESS_415427] calculated.
9.3. Statistical Analyses
The SAP will be developed and finalized before any analyses are performed and will 
describe the analyses and procedures for accounting for missing, unused, and spurious data.This section is a summary of the planned statistical analyses of the primary and secondary endpoints.
9.3.1. Safety Analyses
All safety analyses will be performed on the safety population (safety analysis set).
AEs, ECGs, BP, pulse rate, respi[INVESTIGATOR_697], temperature, continuous cardiac monitoring, and 
safety laboratory data will be reviewed and summarized on an ongoing basis during the study to evaluate the safety of participants. Any clinical laboratory, ECG, BP, pulse rate, respi[INVESTIGATOR_336250]. Safety data will be presented in tabular and/or graphical format and summarized descriptively, where appropriate.
Medical history and physical examination and neurological examination information, as 
applicable, collected during the course of the study, will be considered source data and will not be required to be reported, unless otherwise noted. However, any untoward findings identified on physical and/or neurological examinations conducted during the active collection period will be captured as AEs, if those findings meet the definition of an AE. 
Data collected at screening that are used for inclusion/exclusion criteria, such as laboratory 
data, ECGs, and vital signs, will be considered source data, and will not be required to be reported, unless otherwise noted. Demographic data collected at screening will be reported.
[IP_ADDRESS]. Electrocardiogram Analyses
Changes from baseline for the ECG parameters HR, QT interval, QTcF, PR interval, and 
QRS complex will be summarized by [CONTACT_22841]. The frequency of uncorrected QT values above 500 ms will be tabulated.
The number (%) of participants with maximum post-dose QTcF values and maximum 
increases from baseline in the following categories will be tabulated by [CONTACT_3148]: 
Safety QTcF Assessment
Degree of Prolongation Mild (ms) Moderate (ms) Severe (ms)090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 68Absolute value >450 ‑480 >480 ‑500 >500
Increase from baseline 30 ‑60 >60
If more than 1 ECG is collected at a nominal time after dose administration (for example, 
triplicate ECGs), the mean of the replicate measurements will be used to represent a single observation at that time point. If any of the 3 individual ECG tracings has a QTcF value >500 ms, but the mean of the triplicates is not >500 ms, the data from the participant’s individual tracing will be described in a safety section of the CSR in order to place the >500 ms value in appropriate clinical context. However, values from individual tracings within triplicate measurements that are >500 ms will not be included in the categorical analysis unless the average from the triplicate measurements is also >500 ms. Changes from baseline will be defined as the change between the postdose QTcF value and the average of the pre-dose triplicate values at -1, -0.5, and 0 hours pre-dose on Day 1.
In addition, an attempt will be made to explore and characterize the relationship between 
plasma concentration and QT interval length using a PK/PD modeling approach. If a PK/PD relationship is found, the impact of participant factors (covariates) on the relationship will be examined. The results of such analyses may not be included in the CSR.
9.3.2. PK Analysis
The PK concentration and parameter populations are defined in Section 9.2.
[IP_ADDRESS]. Derivation of PF-[ADDRESS_415428] quantifiable concentration (C
last)Linear/Log trapezoidal method
AUC inf*Area under the plasma 
concentration-time profile from 
time [ADDRESS_415429]+ (C last*/k el), where C last* is the predicted 
plasma concentration at the last quantifiable 
timepoint estimated from the log-linear 
regression analysis
Cmax Maximum plasma concentration Observed directly from data
Tmax Time for C max Observed directly from data as time of first occurrence
t½*Terminal elimination half-life Log e(2)/k el, where k el is the terminal phase rate 
constant calculated by a linear regression of the log-linear concentration-time curve. Only those 090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 69Table 4. Plasma PF-06954522 PK Parameters
Parameter Definition Method of Determination
data points judged to describe the terminal log-linear decline will be used in the regression.
CL/F*Apparent clearance Dose/AUC inf
Vz/F*Apparent volume of distribution Dose/(AUC inf&kel)
AUC last(dn) Dose-normalized AUC last AUC last/Dose
AUC inf(dn)*Dose-normalized AUC inf AUC inf/Dose
Cmax(dn) Dose-normalized C max Cmax/Dose
*As data permits.
[IP_ADDRESS]. Statistical Methods for PK Data
Plasma concentrations of PF-06954522 will be listed and summarized descriptively by [CONTACT_2715] 
(and fasting condition and ethnicity, if appropriate) and nominal PK sampling time. Individual participant and median profiles of the plasma concentration-time data will be plotted by [CONTACT_2715] (and fasting condition and ethnicity, if appropriate) using actual (for individual) and nominal (for median) times respectively. Median profiles will be presented on both linear and semi-log scales.
The plasma PK parameters will be summarized descriptively by [CONTACT_2715] (and fasting condition 
and ethnicity, if appropriate) as applicable. Dose-normalized AUC
inf, AUC last, and C maxwill 
be plotted against dose (and fasting condition and ethnicity, if appropriate) using box andwhisker plots and will include individual participant values and the geometric means for each dose. These plots will be used to understand the relationship between PK parameters and dose (and fasting condition and ethnicity, if appropriate).
If the food effect is assessed, a mixed effects ANOVA will be performed separately on the 
natural log transformed AUC
inf, AUC last, and C max(dose-normalized prior to analysis, if 
appropriate) with fasting condition included as a fixed effect and participant as a random effect. Further details of this analysis will be provided in the SAP.
Additional PK analyses may be performed if deemed appropriate and may not be included in 
the CSR.
9.3.3. Tertiary/Exploratory Endpoint(s) Analysis
The analysis of tertiary/exploratory endpoints will be detailed in the SAP.
9.3.4. Other Analyses 
Pharmacogenomic or biomarker data from Retained Research Samples may be collected 
during or after the trial and retained for future analyses; the results of such analyses are not planned to be included in the CSR.090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 709.4. Interim Analyses
No formal interim analysis will be conducted for this study.9.5. Sample Size Determination
A sufficient number of participants will be screened to achieve approximately 24 participants 
(up to 3 cohorts of up to approximately 10, 8 and 6 participants in Cohorts 1, 2, and 3, respectively) randomized. This sample size of approximately [ADDRESS_415430] exposure to humans of a new chemical entity and the requirement to provide adequate safety, tolerability, and PK assessment at each dose level.
In each period of Cohort 1, approximately 8 participants are planned to receive 
PF-06954522, and 2 participants are planned to receive placebo; with all participants inCohort 1 at the end of the study having received up to 5 doses of PF-06954522 and up to 2 doses of placebo.
In each period of Cohort 2, approximately 6 participants are planned to receive
PF-06954522, and 2 participants are planned to receive placebo; with all participants in Cohort 2 at the end of the study having received up to 4 doses of PF-06954522 and up to 2 doses of placebo.
An optional cohort of Japanese participants (Cohort 3) with a target sample size of 
approximately 6 participants (approximately 4 receiving PF-06954522, approximately 2 receiving placebo in each period) may also be enrolled, if feasible. The actual number of Japanese participants may be adjusted based on emerging data or operational factors, with a maximum sample size of up to 8 participants (6 receiving PF-06954522 and 2 receivingplacebo in each period). 090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 7110. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations10.1.1. Regulatory and Ethical ConsiderationsThis study will be conducted in accordance with the protocol and with the following:
!Consensus ethical principles derived from international guidelines, including the 
Declaration of Helsinki and CIOMS International Ethical Guidelines;
!Applicable ICH-GCP guidelines;
!Applicable laws and regulations, including applicable privacy laws.
The protocol, protocol amendments, ICD, SRSD(s), and other relevant documents 
(eg, advertisements) must be reviewed and approved by [CONTACT_456], submitted to an IRB/EC by [CONTACT_093], and reviewed and approved by [CONTACT_1201]/EC before the study is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate hazard to study participants.
Protocols and any substantial amendments to the protocol will require health authority 
approval prior to initiation except for changes necessary to eliminate an immediate hazard to study participants.
The investigator will be responsible for the following:
!Providing written summaries of the status of the study to the IRB/EC annually or 
more frequently in accordance with the requirements, policies, and procedures established by [CONTACT_1201]/EC;
!Notifying the IRB/EC of SAEs or other significant safety findings as required by 
[CONTACT_1744]/EC procedures;
!Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH-GCP guidelines, the IRB/EC, European regulation 
536/2014 for clinical studies, European Medical Device Regulation 2017/745 for clinical device research, and all other applicable local regulations.
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of any prohibition or restriction imposed (ie, clinical hold) by [CONTACT_22844], or if the investigator is aware of any new information that might influence the evaluation of the benefits and risks of the study intervention, [COMPANY_007] should be informed immediately.090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 72In addition, the investigator will inform [COMPANY_007] immediately of any urgent safety measures 
taken by [CONTACT_22845], and of any serious breaches of this protocol or of the ICH GCP guidelines that the investigator becomes aware of.
10.1.2. Financial Disclosure
Not applicable.
10.1.3. Informed Consent Process
The investigator or the investigator’s representative will explain the nature of the study, 
including the risks and benefits, to the participant and answer all questions regarding the study. The participant should be given sufficient time and opportunity to ask questions and to decide whether or not to participate in the trial.
Participants must be informed that their participation is voluntary. Participants will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, privacy and data protection requirements, where applicable, and the IRB/EC or study center.
The investigator must ensure that each participant is fully informed about the nature and 
objectives of the study, the sharing of data related to the study, and possible risks associated with participation, including the risks associated with the processing of the participant’s personal data. 
The participant must be informed that their personal study-related data will be used by [CONTACT_20004]. The level of disclosure must also be explained to the participant.
The participant must be informed that their medical records may be examined by [CONTACT_11000], by[CONTACT_6667]/EC members, and by [CONTACT_6668].
The investigator further must ensure that each study participant is fully informed about their
right to access and correct their personal data and to withdraw consent for the processing of their personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study and the date on which the written consent was obtained. The authorized person obtaining the informed consent must also sign the ICD.
Participants must be reconsented to the most current version of the IRB/EC-approved ICD(s) 
during their participation in the study as required per local regulations.
A copy of the ICD(s) must be provided to the participant.Participants who are rescreened are required to sign a new ICD.090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 7310.1.3.1. Electronic Consent 
Participants may be able to experience the informed consent process by [CONTACT_10075] 
(eConsent). The eConsent process includes an electronic presentation of the informed consent document (eICD), clinical trial educational components (as applicable), and electronic signatures (if allowed by [CONTACT_427]). The use of eConsent does not replace or alter the ICD content or informed consent process as described above. The eConsent process complies with applicable regulations and sponsor policies to ensure reliability and data privacy. 
10.1.4. Data ProtectionAll parties will comply with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study site in encrypted electronic and/or paper
form and will be password protected or secured in a locked room to ensure that only authorized study staff have access. The study site will implement appropriate technical and organizational measures to ensure that the personal data can be recovered in the event of disaster. In the event of a potential personal data breach, the study site will be responsible for determining whether a personal data breach has in fact occurred and, if so, providing breach notifications as required by [CONTACT_2371].
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant-specific numerical code. Any participant records or data sets that are transferred to the sponsor will contain the numerical code; participant names will not be transferred. All other identifiable data transferred to the sponsor will be identified by [CONTACT_20007], participant-specific code. The study site will maintain a confidential list of participants who participated in the study, linking each participant’s numerical code to their actual identity and medical record ID. In case of data transfer, the sponsor will protect the confidentiality of participants’ personal data consistent with the clinical study agreement and applicable privacy laws.
Information technology systems used to collect, process, and store study-related data are 
secured by [CONTACT_336272], alteration, or unauthorized disclosure or access.
The sponsor maintains SOPs on how to respond in the event of unauthorized access, use, or 
disclosure of sponsor information or systems.
10.1.5. Committees Structure
[IP_ADDRESS]. Data Monitoring Committee This study will not use an E-DMC.
10.1.6. Dissemination of Clinical Study Data
[COMPANY_007] fulfills its commitment to publicly disclose clinical study results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT/CTIS, and/or 090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 74www.pfizer.com, and other public registries and websites in accordance with applicable local 
laws/regulations. In addition, [COMPANY_007] reports study results outside of the requirements of local laws/regulations pursuant to its SOPs.
In all cases, study results are reported by [CONTACT_4715], accurate, balanced, and 
complete manner and are reported regardless of the outcome of the study or the country in which the study was conducted.
www.clinicaltrials.gov[COMPANY_007] posts clinical trial results on www.clinicaltrials.gov for [COMPANY_007]-sponsored interventional 
studies (conducted in patients) that evaluate the safety and/or efficacy of a product, regardless of the geographical location in which the study is conducted. These results are submitted for posting in accordance with the format and timelines set forth by [CONTACT_20008].
EudraCT/CTIS
[COMPANY_007] posts clinical trial results on EudraCT/CTIS for [COMPANY_007]-sponsored interventional studies 
in accordance with the format and timelines set forth by [CONTACT_20009].
www.pfizer.com[COMPANY_007] posts CSR synopses and plain-language study results summaries on www.pfizer.com 
for [COMPANY_007]-sponsored interventional studies at the same time the corresponding study results are posted to www.clinicaltrials.gov. CSR synopses will have personally identifiable information anonymized.
Documents within marketing applications
[COMPANY_007] complies with applicable local laws/regulations to publish clinical documents included 
in marketing applications. Clinical documents include summary documents and CSRs including the protocol and protocol amendments, sample CRFs, and SAPs. Clinical documents will have personally identifiable information anonymized.
Data sharing
[COMPANY_007] provides researchers secure access to participant-level data or full CSRs for the 
purposes of “bona-fide scientific research” that contributes to the scientific understanding of the disease, target, or compound class. [COMPANY_007] will make data from these trials available [ADDRESS_415431], including individuals requesting access for commercial/competitive or legal purposes.090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 7510.1.7. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically (eg, laboratory data). The investigator is responsible for verifying that data entries  are accurate and correct by [CONTACT_18027].
Guidance on completion of CRFs will be provided in the CRF Completion Requirements 
document.
The investigator must ensure that the CRFs are securely stored at the study site in encrypted 
electronic and/or paper form and are password-protected or secured in a locked room to prevent access by [CONTACT_20011].
The investigator must permit study-related monitoring, audits, IRB/EC review, and 
regulatory agency inspections and provide direct access to source records and documents.This verification may also occur after study completion. It is important that the investigator(s) and their relevant personnel are available during the monitoring visits and possible audits or inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy, including definition of study-critical data items and 
processes (eg, risk-based initiatives in operations and quality, such as risk management and mitigation strategies and analytical risk-based monitoring), methods, responsibilities, and requirements, including handling of noncompliance issues and monitoring techniques (central, virtual, or on-site monitoring), are provided in the data management plan and IQMPmaintained and utilized by [CONTACT_36613].
The sponsor or designee is responsible for the data management of this study, including 
quality checking of the data.
Records and documents, including signed ICDs, pertaining to the conduct of this study must 
be retained by [CONTACT_1732] [ADDRESS_415432] ensure that the records continue to be stored securely for as long as they are maintained.
When participant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_306891].
The investigator(s) will notify the sponsor or its agents immediately of any regulatory 
inspection notification in relation to the study. Furthermore, the investigator will cooperate with the sponsor or its agents to prepare the investigator site for the inspection and will allow the sponsor or its agent, whenever feasible, to be present during the inspection. The investigator site and investigator will promptly resolve any discrepancies that are identified between the study data and the participant’s medical records. The investigator will promptly 090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 76provide copi[INVESTIGATOR_19946]. Before response 
submission to the regulatory authorities, the investigator will provide the sponsor or its agents with an opportunity to review and comment on responses to any such findings.
10.1.8. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the investigator site.
Data reported on the CRF or entered in the eCRF that are from source documents must be 
consistent with the source documents or the discrepancies must be explained. The investigator may need to request previous medical records or transfer records, depending on the study. Also, current medical records must be available.
Definition of what constitutes a source document and its origin can be found in the Source 
Document Locator, which is maintained by [CONTACT_456]’s designee ([COMPANY_007] CRU).
Description of the use of the computerized system is documented in the Data Management 
Plan, which is maintained by [CONTACT_456]’s designee ([COMPANY_007] CRU).
The investigator must maintain accurate documentation (source record) that supports the 
information entered in the CRF.
The sponsor or designee will perform monitoring to confirm that data entered into the CRF 
by [CONTACT_1191], complete, and verifiable from source documents; that the safety and rights of participants are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP guidelines, and all applicable regulatory requirements.
10.1.9. Use of Medical Records
There may be instances when copi[INVESTIGATOR_336251], where ethically and scientifically justified and permitted by [CONTACT_427], to ensure participant safety.
Due to the potential for a participant to be re-identified from their medical records, the 
following actions must be taken when medical records are sent to the sponsor or sponsor designee:
!The investigator or site staff must redact personal information from the medical 
record. The personal information includes, but is not limited to, the following: participant names or initials, participant dates (eg, birth date, date of hospi[INVESTIGATOR_15517]/discharge, date of death), participant identification numbers (eg, Social 
Security number, health insurance number, medical record number, hospi[INVESTIGATOR_307]/institution identifier), participant location information (eg, street address, 
city, country, postal code, IP address), participant contact [CONTACT_3031] (eg, 
telephone/fax number, email address) .090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 77!Each medical record must be transmitted to the sponsor or sponsor designee using 
systems with technical and organizational security measures to ensure the protection of personal data (eg, Florence is the preferred system if available). 
There may be unplanned situations where the sponsor may request medical records (eg, 
sharing medical records so that the sponsor can provide study-related advice to the investigator). The medical records should be submitted according to the procedure described above.
10.1.10. Study and Site Start and Closure
The study start date is the date of the first participant’s first visit.
The sponsor designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the sponsor, including (but not limited to) regulatory authority decision, change in opi[INVESTIGATOR_1100]/EC, or change in benefit-risk assessment. Study sites will be closed upon study completion. A study site is considered closed when all required documents and study supplies have been collected and a study-site closure visit has been performed.
The investigator may initiate study-site closure at any time upon notification to the sponsor if 
requested to do so by [CONTACT_22846]/EC or if such termination is required to protect the health of study participants.
Reasons for the early closure of a study site by [CONTACT_19711]:
!Failure of the investigator to comply with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor’s procedures, or the ICH-GCP guidelines;
!Inadequate recruitment of participants by [CONTACT_093];
!Discontinuation of further study intervention development.
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the ECs/IRBs, the regulatory authorities, and any CRO(s) used in the study of the reason for termination or suspension, as specified by [CONTACT_1214]. The investigator shall promptly inform the participant and should assure appropriate participant therapy and/or follow-up.
Study termination is also provided for in the clinical study agreement. If there is any conflict 
between the contract and this protocol, the contract will control as to termination rights.
10.1.11. Publication Policy
The investigator agrees to refer to the primary publication in any subsequent publications. 
[COMPANY_007] will not provide any financial compensation for the investigator’s participation in the 090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 78preparation of the primary congress abstract, poster, presentation, or primary manuscript for 
the study.
Investigators are free to publish individual center results that they deem to be clinically 
meaningful after publication of the overall results of the study or [ADDRESS_415433] to the other requirements described in this section.
The investigator will provide [COMPANY_007] an opportunity to review any proposed publication or 
any other type of disclosure of the study results (collectively, “publication”) before it is submitted or otherwise disclosed and will submit all publications to [COMPANY_007] [ADDRESS_415434], remove any previously undisclosed confidential information before disclosure, except for any study-intervention or [COMPANY_007]-related information necessary for the appropriate scientific presentation or understanding of the study results. For joint publications, should there be disagreement regarding interpretation and/or presentation of specific analysis results, resolution of, and responsibility for, such disagreements will be the collective responsibility of all authors of the publication.
For all publications relating to the study, the investigator and [COMPANY_007] will comply with 
recognized ethical standards concerning publications and authorship, including those established by [CONTACT_4717]. The investigator will disclose any relationship with [COMPANY_007] and any relevant potential conflicts of interest, including any financial or personal relationship with [COMPANY_007], in any publications. All authors will have access to the relevant statistical tables, figures, and reports (in their original format) required to develop the publication.
10.1.12. Sponsor’s Medically Qualified Individual
The contact [CONTACT_1133]’s MQI for the study is documented in the study 
contact [CONTACT_336273].
To facilitate access to their investigator and the sponsor’s MQI for study-related medical 
questions or problems from non-study healthcare professionals, participants are provided 
with an ECC at the time of informed consent. The ECC contains, at a minimum, (a) protocol 
and study intervention identifiers, (b) participant’s study identification number, (c) site emergency phone number active 24 hours/day, [ADDRESS_415435], the established communication pathways 
between the participant and their investigator and site staff, and between the investigator and sponsor study team. The ECC is only to be used by [CONTACT_336274], as a means of reaching the investigator or site staff related to the care of a participant. 090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 7910.2. Appendix 2: Clinical Laboratory Tests
The following safety laboratory tests will be performed at times defined in the SoA section of 
this protocol. Additional laboratory results may be reported on these samples as a result of the method of analysis or the type of analyzer used by [CONTACT_20019], or as derived from calculated values; for example: calculation of estimated kidney function (ie, [ADDRESS_415436]). These additional tests would not require additional collection of blood. Unscheduled clinical laboratory measurements may be obtained at any time during the study to assess any perceived safety issues.
Table 5. Protocol -Required Laboratory Assessments
Hematology Chemistry Urinalysis Other
Hemoglobin
Hematocrit
RBC count
MCV, MCH, MCHCPlatelet countWBC countTotal neutrophils (Abs)Eosinophils (Abs)
Monocytes (Abs)
Basophils (Abs)Lymphocytes (Abs)BUN
Creatinine
Cystatin C
a
eGFRb
Glucose (fasting)
CalciumSodiumPotassium
Chloride
Total CO
2(bicarbonate)
AST, ALTTotal bilirubinDirect and indirect bilirubin
c
GGT
Alkaline phosphatase
Creatine Kinase (CK)Uric acidAlbuminTotal proteinLocal dipstick
g:
pH
Glucose (qual)
Protein (qual)Blood (qual)KetonesNitritesLeukocyte esterase
Urobilinogen
Urine bilirubin
Laboratory:
Microscopy and 
culturedFSHe,f
HBcAbf
HBsAbf
HBsAgf
HCVAbf
HIVf
HbA1cf
TSHf
Urine albumin to creatinine ratio (quantitative)
f,h
Urine drug screeni
Calcitoninj
Amylasej
Lipasej
Total bile acidsj
a. Serum Cystatin C (Scys): Screening or Baseline Scys is recommended to help differentiate post-baseline DIKI from 
DICI. Post-baseline, Scys is measured if and only if serum creatinine increase is observed (see Section 7.1.1 ).
b. Screening and Baseline eGFR is measured with Screat-based formula. Age-specific kidney function calculation (see 
Section 10.7.2 ) is recommended to assess presence or absence of post-baseline change in kidney function.
c. Test as reflex if total bilirubin is elevated.d. Only if UTI is suspected and urine dipstick is positive for nitrites or leukocyte esterase or both.e. For confirmation of postmenopausal status only in females <60 years old and not using hormonal or HRT only.f. At screening only.
g. Assessed by [CONTACT_72502].
h. Assessed by [CONTACT_336275].i. At screening and upon admission for each inpatient stay. The minimum requirement for drug screening includes 
cocaine, THC, opi[INVESTIGATOR_858]/opi[INVESTIGATOR_2438], benzodiazepi[INVESTIGATOR_1651], and amphetamines (others are site- and study-specific).
j. Review of these data is not required prior to dosing and dose escalation in each period; cumulative results will be 
reviewed as they become available.090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 80Table 6. Protocol-Required Laboratory Assessments – Reflex Testing
Hematology Chemistry Urinalysis on Site Other
If Hb/RBC abnormal: MCV, MCH, MCHC 
Neutrophils (%) 
Eosinophils (%) Basophils (%) Lymphocytes (%) Monocytes (%) RBC morphology 
RBC distribution widthRequired:
For suspected DILI:
AST/ALT 
T bili, albumin, CK, direct and indirect bili GGT, PT/INR, eosinophils (%), alkaline phosphatase
The following additional 
testing may be warranted:Acetaminophen/paracetamol or protein adduct levels Hepatitis serology (even if 
screening negative) 
Total bile acidsLiver imaging
For suspected DICI/DIKI: 
Creatinine (Screat)
Cystatin Ca(Scys)
eGFR (Screat only and combined Screat+Scys)
b
Urine albumin-to-
creatinine-ratio (UACR) Local Laboratory
Microscopy and 
culture for positive 
local dipstick testscHepatitis B DNA Hepatitis C RNA
a. Cystatin C (Scys): Screening or Baseline Scys is recommended to help differentiate post-baseline DIKI from 
DICI. Post-baseline, Scys is measured if and only if clinically-relevant serum creatinine increase post-baseline isobserved (see Section 7.1.1 ).
b. Creatinine (Screat): Screening and Baseline eGFR is measured with Screat-based formula. Age-specific kidney 
function calculation (see Section 10.7.2 ) is recommended to assess the presence or absence of post-baseline 
change in kidney function.
c. Only if UTI is suspected and urine dipstick is positive for nitrites or leukocyte esterase or both. Any positive 
results are to be reported as an AE.
The investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the CRF.
Laboratory/analyte results that could unblind the study and have been collected for the 
purpose of the study will not be reported to investigator sites or other blinded personnel until the study has been unblinded.
Any remaining serum/plasma from samples collected for clinical safety laboratory 
measurements at baseline and at all times after dose administration may be retained and stored for the duration of the study. Upon completion of the study, these retained safety samples may be used for the assessment of exploratory safety biomarkers or unexpected safety findings. These data will not be included in the CSR. Samples to be used for this purpose will be shipped to either a [COMPANY_007]-approved BBS facility or other designated laboratory and retained for up to 1 year following the completion of the study.090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 84nonserious AEs; and (3) exposure to the study intervention under study during 
pregnancy or breastfeeding, and occupational exposure. 
It should be noted that the CT SAE Report Form for reporting of SAE information is not 
the same as the AE page of the CRF. When the same data are collected, the forms must be completed in a consistent manner. AEs should be recorded using concise medical terminology and the same AE term should be used on both the CRF and the CT SAE Report Form for reporting of SAE information.
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to [COMPANY_007] Safety Within 24 Hours of Awareness
SAE All All
Nonserious AE All None
Exposure to the study intervention under study during pregnancy or breastfeedingAll AEs/SAEs associated 
with EDP or EDB
Note: Instances of EDP or 
EDB not associated with an AE or SAE are not captured in the CRFAll instances of EDP are 
reported (whether or not there is an associated SAE)*
All instances of EDB are 
reported (whether or not there is an associated SAE)**
Environmental or occupational exposure to the product under study to a nonparticipant (not involving EDP or EDB)None. Exposure to a study 
non-participant is not collected on the CRFThe exposure (whether or 
not there is an associated AE or SAE) must be reported***
*EDP (with or without an associated SAE): is reported to [COMPANY_007] Safety using the CT SAE Report 
Form and EDP Supplemental Form. 
** EDB is reported to [COMPANY_007] Safety using the CT SAE Report Form, which would also include 
details of any SAE that might be associated with the EDB. 
***Environmental or occupational exposure: AEs or SAEs associated with occupational exposure 
are reported to [COMPANY_007] Safety using the CT SAE Report Form. 
!When an AE or SAE occurs, it is the responsibility of the investigator to review 
all documentation (eg, hospi[INVESTIGATOR_1088], laboratory reports, and diagnostic 
reports) related to the event.
!The investigator will then record all relevant AE or SAE information in the CRF.090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 8810.4. Appendix 4: Contraceptive and Barrier Guidance
10.4.1. Male Participant Reproductive Inclusion CriteriaMale participants are eligible to participate if they agree to the following requirements during 
the intervention period and for at least [ADDRESS_415437] dose of study intervention, which corresponds to the time needed to eliminate reproductive safety risk of the study intervention(s): 
!Refrain from donating sperm.
PLUS either :
!Be abstinent from heterosexual intercourse as their preferred and usual lifestyle 
(abstinent on a long-term and persistent basis) and agree to remain abstinent.
OR
!Must agree to use contraception/barrier as detailed below:
!Agree to use a male condom, and should also be advised of the benefit for 
a female partner to use a highly effective method of contraception, as a condom may break or leak when having sexual intercourse with a WOCBP who is not currently pregnant.
!In addition to male condom use, a highly effective method of 
contraception may be considered in WOCBP partners of male participants 
(refer to the list of highly effective methods below in Section 10.4.4 ).
10.4.2. Female Participant Reproductive Inclusion Criteria
The criteria below are part of Inclusion Criterion 1 (Age and Sex; Section 5.1 ) and specify 
the reproductive requirements for including female participants. Refer to Section 10.4.[ADDRESS_415438] of contraceptive methods permitted in the study. 
!A female participant is eligible to participate if she (a) is not pregnant or 
breastfeeding; and (b) agrees not to donate eggs (ova, oocytes) for the purpose of 
reproduction for at least [ADDRESS_415439] dose of study intervention; and (c) Is not a WOCBP (see definition in Section 10.4.3 ).
The investigator is responsible for review of medical history, menstrual history, and recent 
sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy. 090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 8910.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanently sterile (see below).
If fertility is unclear (eg, amenorrhea or oligomenorrhea) and a menstrual cycle cannot be 
confirmed before the first dose of study intervention, additional evaluation should be considered.
Women in the following categories are not considered WOCBP:
1. Premenarchal.2. Premenopausal female with 1 of the following:
!Documented hysterectomy;
!Documented bilateral salpi[INVESTIGATOR_1656];
!Documented bilateral oophorectomy.
For individuals with permanent infertility due to a medical cause other than the above
(eg, mullerian agenesis, androgen insensitivity), investigator discretion should be applied to determining study entry.
Note: Documentation for any of the above categories can come from the site personnel’s 
review of the participant’s medical records, medical examination, or medical history interview. The method of documentation should be recorded in the participant’s medical record for the study.
3. Postmenopausal female.
!A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. In addition:
!A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 60 years old and not using hormonal contraception or HRT. 
!A female on HRT and whose menopausal status is in doubt will be required to 
use one of the highly effective nonestrogen hormonal contraception methods 
if she wishes to continue her HRT during the study. Otherwise, she must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 9010.4.4. Contraception Methods
Contraceptive use by [CONTACT_336276]/regulations regarding the use of contraceptive methods for those participating in clinical trials.
The following contraceptive methods for male participants or their female partners who are 
of childbearing potential are appropriate for this study:
Highly Effective Methods That Have Low User Dependency 
1. Implantable progestogen-only hormone contraception associated with inhibition of 
ovulation.
2. Intrauterine device.3. Intrauterine hormone-releasing system.4. Bilateral tubal occlusion.5. Vasectomized partner.
!Vasectomized partner is a highly effective contraceptive method provided that the 
partner is the sole sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used. The spermatogenesis cycle is approximately 90 days.
Highly Effective Methods That Are User Dependent 
6. Combined (estrogen- and progestogen-containing) hormonal contraception associated 
with inhibition of ovulation:
!Oral + barrier *
!Intravaginal + barrier *
!Transdermal + barrier *
7. Progestogen-only hormone contraception associated with inhibition of ovulation:
!Oral + barrier *
!Injectable + barrier *
8. Sexual Abstinence
Sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 91with the study intervention. The reliability of sexual abstinence needs to be evaluated 
in relation to the duration of the study and the preferred and usual lifestyle of the participant.
* Acceptable barrier methods to be used concomitantly with options 6 or 7 for the study 
include any of the following:
!Male or female condom with or without spermicide;
!Cervical cap, diaphragm, or sponge with spermicide;
!A combination of male condom with either cervical cap, diaphragm, or sponge 
with spermicide (double-barrier methods).090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 9210.5. Appendix 5: Genetics
Use/Analysis of DNA
!Genetic variation may impact a participant’s response to study intervention, 
susceptibility to, and severity and progression of disease. Therefore, where local regulations and IRBs/ECs allow, a blood sample will be collected for DNA analysis.
!The scope of the genetic research may be narrow (eg, 1 or more candidate genes) or
broad (eg, the entire genome), as appropriate to the scientific question under investigation.
!The samples may be analyzed as part of a multistudy assessment of genetic factors 
involved in the response to study intervention or study interventions of this class to understand treatments for the disease(s) under study or the disease(s) themselves.
!The results of genetic analyses may be reported in the CSR or in a separate study 
summary, or may be used for internal decision making without being included in a study report.
!The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality. 
!The samples will be retained as indicated:
!Retained samples will be stored indefinitely or for another period as per local 
requirements.
!Participants may withdraw their consent for the storage and/or use of their Retained 
Research Samples at any time by [CONTACT_7328] a request to the investigator; in this case, any remaining material will be destroyed. Data already generated from the samples will be retained to protect the integrity of existing analyses.
!Samples for genetic research will be labeled with a code. The key between the code 
and the participant’s personally identifying information (eg, name, address) will be held securely at the study site.090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 9310.6. Appendix 6: Liver Safety: Suggested Actions and Follow-Up Assessments
Potential Cases of Drug-Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury (as determined by [CONTACT_20023]) are termed “tolerators,” while those who show transient liver injury but adapt are termed “adaptors.” In some participants, transaminase elevations are a harbinger of a more serious potential outcome. These participants fail to adapt and therefore are “susceptible” to progressive and serious liver injury, commonly referred to as DILI. Participants who experience a transaminase elevation above 3 × ULN should be monitored more frequently to determine if they are “adaptors” or are “susceptible.”
In the majority of DILI cases, elevations in AST and/or ALT precede T bili elevations 
(>2 × ULN) by [CONTACT_22857]. The increase in T bili typi[INVESTIGATOR_161651]/ALT is/are still elevated above 3 × ULN (ie, AST/ALT and T bili values will be elevated within the same laboratory sample). In rare instances, by [CONTACT_29623] T bili elevations are detected, AST/ALT values might have decreased. This occurrence is still regarded as a potential DILI. Therefore, abnormal elevations in either AST or ALT in addition to T bili that meet the criteria outlined below are considered potential DILI (assessed per Hy’s law criteria) cases and should always be considered important medical events, even before all other possible causes of liver injury have been excluded.
The threshold of laboratory abnormalities for a potential DILI case depends on the 
participant’s individual baseline values and underlying conditions. Participants who present with the following laboratory abnormalities should be evaluated further as potential DILI (Hy’s law) cases to definitively determine the etiology of the abnormal laboratory values:
!Participants with AST/ALT and T bili baseline values within the normal range who 
subsequently present with AST OR ALT values ≥3 × ULN AND a T bili value ≥2 × ULN 
with no evidence of hemolysis and an alkaline phosphatase value <2 × ULN or not available.
!For participants with baseline AST OR ALT ORT bili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, depending on which values are above the ULN at baseline:
!Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values ≥2 times the baseline values AND ≥3 × ULN; or ≥8 × ULN (whichever is 
smaller).
!Preexisting values of T bili above the normal range: T bili level increased from 
baseline value by [CONTACT_219911] ≥1 × ULN orif the value reaches ≥3 × ULN 
(whichever is smaller).
Rises in AST/ALT and T bili separated by [CONTACT_726] a few weeks should be assessed 
individually based on clinical judgment; any case where uncertainty remains as to whether it represents a potential Hy’s law case should be reviewed with the sponsor. 090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 94The participant should return to the investigator site and be evaluated as soon as possible, 
preferably within [ADDRESS_415440] and ALT and T bili for suspected Hy’s law 
cases, additional laboratory tests should include albumin, CK, direct and indirect bilirubin, GGT, PT/INR, eosinophils (%), and alkaline phosphatase. Consideration should also be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further testing, as needed, for further contemporaneous analyses at the time of the recognized initial abnormalities to determine etiology. A detailed history, including relevant information, such as review of ethanol, acetaminophen/paracetamol (either by [CONTACT_20025] a coformulated product in prescription or over-the-counter medications), recreational drug, or supplement (herbal) use and consumption, family history, sexual history, travel history, history of contact [CONTACT_4490] a jaundiced person, surgery, blood transfusion, history of liver or allergic disease, and potential occupational exposure to chemicals, should be collected. Further testing for acute hepatitis A, B, C, D, and E infection, total bile acids, liver imaging (eg, biliary tract), and collection of serum samples for acetaminophen/paracetamol drug and/or protein adduct levels may be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory criteria of AST/ALT and 
T bili elevation defined above should be considered potential DILI (Hy’s law) cases if no other reason for the LFT abnormalities has yet been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy’s law) case becomes a confirmed case only after all results of 
reasonable investigations have been received and have excluded an alternative etiology.090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 9510.7. Appendix 7: Kidney Safety: Monitoring Guidelines
10.7.1. Laboratory Assessment of Change in Kidney Function and Detection of Kidney 
Injury
Standard kidney safety monitoring requires assessment of baseline and postbaseline Screat 
measurement to estimate kidney function [eg, Screat-based eGFR]. Obtaining Screening or Baseline Scys and postbaseline reflex Scys (if confirmed Screat increase ≥0.3 mg/dL) makes 
it feasible to distinguish AKI from DICI. If Screat increase is confirmed after baseline, then reflex measurement of Scys is indicated:
ADULTS: Currently, 2021 CKD-EPI [INVESTIGATOR_336252] (Screat only-based and combined 
Screat plus Scys-based) are valid for use in adults only. At baseline Screat and Scys values are needed to calculate 2021 CKD-EPI [INVESTIGATOR_336253]-based equation (see Section [IP_ADDRESS]) and by [CONTACT_336277]-based equation. When post-baseline Screat increase ≥0.3 mg/dL is confirmed, then reflex Scys measurement is needed to enable 
post-baseline comparison of eGFR changes (Screat only-based eGFR and combined Screat plus Scys eGFR). 
10.7.2. Age-Specific Kidney Function Calculation Recommendations
[IP_ADDRESS]. Adults (18 Years and Above)—2021 CKD-EPI [INVESTIGATOR_336254] (mL/min/1.73m²)[ 17]
2021 CKD-
EPI            
[INVESTIGATOR_336255]
(mg/dL)Scys
(mg/L)Recommended eGFR Equation
Female if ≤ 0.7 NA eGFR = 143 × (Screat/0.7)-0.241  ×  (0.9938)Age
Female if > 0.7 NA eGFR = 143 × (Screat/0.7)-1.200  ×  (0.9938)Age
Male if ≤ 0.9 NA eGFR = 142 × (Screat/0.9)-0.302  ×  (0.9938)Age
Male if > 0.9 NA eGFR = 142 × (Screat/0.9)-1.200  ×  (0.9938)Age
2021 CKD-
EPI           
[INVESTIGATOR_227932]-Scys 
CombinedScreat
(mg/dL)Scys
(mg/L)Recommended eGFR Equation
Female if ≤ 0.7 if ≤ 0.8 eGFR = 130 × (Screat/0.7)-0.219  × (Scys/0.8)-0.323  × (0.9961)Age
Female if ≤ 0.7 if > 0.8 eGFR = 130 × (Screat/0.7)-0.219  × (Scys/0.8)-0.778  × (0.9961)Age
Female if > 0.7 if ≤ 0.8 eGFR = 130 × (Screat/0.7)-0.544  × (Scys/0.8)-0.323  × (0.9961)Age
Female if > 0.7 if > 0.8 eGFR = 130 × (Screat/0.7)-0.544  × (Scys/0.8)-0.778  × (0.9961)Age
Male if ≤ 0.9 if ≤ 0.8 eGFR = 135 × (Screat/0.9)-0.144  × (Scys/0.8)-0.323  × (0.9961)Age
Male if ≤ 0.9 if > 0.8 eGFR = 135 × (Screat/0.9)-0.144  × (Scys/0.8)-0.778  × (0.9961)Age
Male if > 0.9 if ≤ 0.8 eGFR = 135 × (Screat/0.9)-0.544  ×  (Scys/0.8)-0.323  × (0.9961)Age
Male if > 0.9 if > 0.8 eGFR = 135 × (Screat/0.9)-0.544  ×  (Scys/0.8)-0.778  × (0.9961)Age
10.7.3. Kidney Function Calculation Tools
The sponsor has provided the following resources to investigational sites when required to 
calculate age-specific kidney function at Screening, Baseline, and post-Baseline visits. Site calculations of kidney function can be performed manually, using the age appropriate formulae (see Section 10.7.2 ) and can use recommended online kidney function calculators 
to reduce the likelihood of a calculation error. 090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 96The [LOCATION_002] National Kidney Foundation Online Calculators. 
!Adults (18 years and above) - 2021 CKD-EPI [INVESTIGATOR_227933] (eGFR): 
https://www.kidney.org/professionals/KDOQI/gfr_calculator
Investigational sites are responsible to ensure that the accurate age-specific equation is 
selected and that the correct units for serum creatinine (mg/dL only), serum cystatin C (mg/L only), total body weight (kg only), and age (years). Investigators are expected to (i) review and confirm correctness of the kidney function calculation results and (ii) evaluate the calculated value within the context of historical information available to them in the participant’s medical record. Investigators are responsible for the clinical oversight of the participant eligibility process, kidney function calculation, and dose selection and adjustments per study protocol. Investigators are encouraged to direct questions or uncertainties regarding kidney function and dosing to the [COMPANY_007] Clinical Team and Medical Monitor, if needed.
10.7.4. Adverse Event Grading for Kidney Safety Laboratory AbnormalitiesAE grading for decline in kidney function will be according to CTCAE criteria.
CTCAE 
Term (2017)Grade 1 Grade 2 Grade 3 Grade 4 Grade 
5
AKI NA NA Hospi[INVESTIGATOR_336256]-threatening 
consequences; dialysis indicatedDeath
AKI:  A disorder characterized by [CONTACT_336278] (within 2 weeks) and is traditionally 
classified as pre-renal (low blood flow into kidneys), renal (kidney damage), or post-renal causes (ureteral or bladder outflow obstruction.
Creatinine increased>ULN to 1.5 ×
ULN>1.5 to 3.0 ×
baseline OR >1.5 to 3.0 × ULN>3.0 to 6.0 ×
baseline OR >3.0 to 6.0 × ULN>6.0 × ULN NA
CKD eGFR ≥60 to 
89 mL/min/1.73m² OR                 eCrCl ≥60 to 80 
mL/min eGFR 30 to 
59 mL/min/1.73m² OR                  eCrCl 30 to 59 mL/mineGFR 15 to 
29 mL/min/1.73m² OR                eCrCl 15 to 29 mL/mineGFR 
<15 mL/min/1.73m² OR       eCrCl <15 mL/min OR  dialysis indicatedDeath
Proteinuria ADULTS: 
Proteinuria 1+ OR   
Proteinuria >0.5 to <1.0 g/24 hADULTS: 
Proteinuria 2+ or 
3+               OR        Proteinuria 1.0 to <3.5 g/24 hADULTS: 
Proteinuria 4+          
OR                Proteinuria ≥3.5 
g/24 h NA NA
CKD: A disorder characterized by [CONTACT_336279].090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
P F -0 6 9 5 4 5 2 2 
Pr ot oc ol C4 0 0 1 0 0 1 
Fi nal Pr ot oc ol, 1 7 J ul y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol T e m plate ( 1 4 A pril 2 0 2 3) 
Pa ge 9 9 1 0. 9. A p pe n di x 9: Pr o hi bite d C o nc o mit a nt Me dic ati o ns T h at M a y Res ult i n D DI 
T he pr o hi bite d c o nc o mita nt me dicati o ns liste d bel o w s h o ul d n ot be ta ke n wit h P F - [ADDRESS_415441] u g cate g ories f or vari o us reas o ns (e g, e mer gi n g D DI res ults f or t he I M P, 
a vaila bilit y  of ne w i nf or mati o n i n literat ure o n t he D DI p ote ntial of ot her dr u gs) , if t he 
o verall b e nefit:ris k assess me nt is n ot i m pacte d or if t he c ha n ges d o n ot si g nifica ntl y  i m pact 
t he safet y of partici pa nts or t he scie ntific val ue of t he trial   
T his is n ot a n all -i ncl usi ve list . Site staff s h o ul d c o ns ult wit h t he s p o ns or or desi g nee wit h 
a n y  q uesti o ns re gar di n g p ote ntial D DI. 
I n vesti gat ors s h o ul d c o ns ult t he pr o d uct la bel f or a n y  ot her me dicati o n use d d uri n g t he st u d y  
f or i nf or mati o n re gar di n g me dicati o n t hat is pr o hi bite d f or c o nc o mita nt use. 0 9 0 1 7 7 e 1 9 e 0f 3 af c\ A p pr o v e d\ A p pr o v e d O n: 1 9- J ul- 2 0 2 3 0 1: 5 5 ( G M T) C CI 
P F -0 6 9 5 4 5 2 2 
Pr ot oc ol C4 0 0 1 0 0 1 
Fi nal Pr ot oc ol, 1 7 J ul y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol T e m plate ( 1 4 A pril 2 0 2 3) 
Pa ge 1 0 0 0 9 0 1 7 7 e 1 9 e 0f 3 af c\ A p pr o v e d\ A p pr o v e d O n: 1 9- J ul- 2 0 2 3 0 1: 5 5 ( G M T) C CI 
P F -0 6 9 5 4 5 2 2 
Pr ot oc ol C4 0 0 1 0 0 1 
Fi nal Pr ot oc ol, 1 7 J ul y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol T e m plate ( 1 4 A pril 2 0 2 3) 
Pa ge 1 0 1 1 0. 1 0. A p pe n di x 1 0 : A b bre vi ati o ns 
T he f oll o wi n g is a list of a b bre viati o ns t hat ma y  be use d i n t he pr ot oc ol. 
A b bre vi ati o n Ter m 
A 1 t o A 3 al b u mi n uria ( K DI G O al b u mi n uria se verit y sta n dar dizati o n) 
A bs a bs ol ute 
A D L acti vit y/ acti vities of dail y li vi n g 
A E a d verse e ve nt 
A E SI a d verse e ve nt of s pecial i nterest 
A KI ac ute ki d ne y  i nj ur y 
A L T ala ni ne a mi n otra nsferase 
A N O V A a nal ys is of varia nce 
A S T as partate a mi n otra nsferase 
A U C area u n der t he c o nce ntrati o n -ti me c ur ve 
A U C 2 4 area u n der t he c o nce ntrati o n -ti me c ur ve fr o m ti me 0 t o 2 4 h o urs 
A U C i nf area u n der t he c o nce ntrati o n -ti me c ur ve fr o m ti me 0 t o i nfi nit y 
A U C i nf ( d n) d ose -n or malize d A U C i nf 
A U C last area u n der t he c o nce ntrati o n -ti me c ur ve fr o m [ADDRESS_415442] ( d n) d ose -n or malize d A U C last 
A V atri o ve ntric ular 
A x M P a u xiliar y  me dici nal pr o d uct 
B A bi oa vaila bilit y 
B B S Bi os peci me n Ba n ki n g S yste m 
B E bi oe q ui vale nce 
B MI b o d y  mass i n de x 
B P bl o o d press ure 
b p m beats per mi n ute 
B U N bl o o d urea nitr o ge n 
Ceff stea d y  state efficaci o us c o nce ntrati o n 
C F R C o de of Fe deral Re g ulati o ns 
CI O M S C o u ncil f or I nter nati o nal Or ga nizati o ns of Me dical Scie nces 
C K creati ne ki nase 
C K D -E PI [INVESTIGATOR_336257] o nic Ki d ne y  Disease Epi [INVESTIGATOR_32450] o g y C olla b orati o n 
C L t otal cleara nce of dr u g fr o m e g, plas ma 
C L / F a p pare nt cleara nce of dr u g fr o m e g, plas ma 
C L p plas ma cleara nce 
Cma x ma xi m u m o bser ve d c o nce ntrati o n 
Cma x ( d n) d ose -n or malize d Cma x 
C O 2 car b o n di o xi de ( bicar b o nate) 0 9 0 1 7 7 e 1 9 e 0f 3 af c\ A p pr o v e d\ A p pr o v e d O n: 1 9- J ul- 2 0 2 3 0 1: 5 5 ( G M T) C CI C CI 
C CI 
P F -0 6 9 5 4 5 2 2 
Pr ot oc ol C4 0 0 1 0 0 1 
Fi nal Pr ot oc ol, 1 7 J ul y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol T e m plate ( 1 4 A pril 2 0 2 3) 
Pa ge [ADDRESS_415443] u g Re g ulati n g A ut h orities Cli ni cal Trials 
(E ur o pea n Cli nical Trials Data base )
F D A F o o d a n d Dr u g A d mi nistrati o n 
FI H first i n h u ma n 
F S H f ollicle -sti m ulati n g h or m o ne 
F/ U f oll o w -u p 0 9 0 1 7 7 e 1 9 e 0f 3 af c\ A p pr o v e d\ A p pr o v e d O n: 1 9- J ul- 2 0 2 3 0 1: 5 5 ( G M T) C CI 
C CI 
C CI C CI 
P F -0 6 9 5 4 5 2 2 
Pr ot oc ol C4 0 0 1 0 0 1 
Fi nal Pr ot oc ol, 1 7 J ul y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol T e m plate ( 1 4 A pril 2 0 2 3) 
Pa ge 1 0 3 A b bre vi ati o n Ter m 
G 1 t o G 5 Gra de ( K DI G O e G F R cate g or y  sta n dar dizati o n) 
G C P G o o d Cli nical Practice 
G G T ga m ma -gl uta m y l tra nsferase 
G L P-[ADDRESS_415444] me nt t hera p y
I B In vesti gat or’s Br oc h ure 
I C D i nf or me d c o nse nt d oc u me nt 
I C H I nter nati o nal C o u ncil f or Har m o nisati o n of Tec h nical 
Re q uire me nts f or P har mace uticals f or H u ma n Use 
I D i de ntificati o n 
I M P i n vesti gati o nal m e dici nal pr o d uct 
I N D In vesti gati o nal Ne w Dr u g 
I N R i nter nati o nal n or malize d rati o 
I P A L I n vesti gati o nal Pr o d uct Acc o u nta bilit y L o g
I P M i n vesti gati o nal pr o d uct ma n ual 
I Q M P i nte grate d q ualit y ma na ge me nt pla n 
I R B Instit uti o nal Re vie w Boar d 
I R C i nter nal re vie w c o m mittee 
I R T Interacti ve Res p o nse Tec h n ol o g y 
I S O I nter nati o nal Or ga nizati o n f or Sta n dar dizati o n 
I V I ntra ve n o us (l y) 
I W R Interacti ve We b Res p o nse 
K Pr o p orti o nalit y  c o nsta nt f or Sc h wartz E q uati o ns ( ki d ne y  f u ncti o n) 
K2E D T A di p otassi u m et h y le ne dia mi netetraacetic aci d 
kel first -or der eli mi nati o n rate c o nsta nt 
K DI G O Ki d ne y  Disease I m pr o vi n g Gl o bal O utc o mes 
L B B B left b u n dle bra nc h bl oc k 
L D H lactate de h y d r o ge nase 
L F T li ver f u ncti o n test 
L P D l ocal pr o d uct d oc u me nt 0 9 0 1 7 7 e 1 9 e 0f 3 af c\ A p pr o v e d\ A p pr o v e d O n: 1 9- J ul- 2 0 2 3 0 1: 5 5 ( G M T) C CI 
C CI C CI 
P F -0 6 9 5 4 5 2 2 
Pr ot oc ol C4 0 0 1 0 0 1 
Fi nal Pr ot oc ol, 1 7 J ul y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol T e m plate ( 1 4 A pril 2 0 2 3) 
Pa ge [ADDRESS_415445] b o 
P C R p ol y merase c hai n reacti o n 
P C R U [COMPANY_007] Cli nical Researc h Unit 
P D p har mac o d y n a mic(s) 
P E p h y sical e xa mi nati o n 
P G x p har mac o ge n o mic(s) 
PI [INVESTIGATOR_32449] i n vesti gat or 
PI B p o w der i n b ottle 
P K p har mac o ki netic(s) 
P S S A [COMPANY_007]'s Seri o us A d verse E ve nt S u b missi o n Assista nt 
P T pr ot hr o m bi n ti me 
P T A p ost -trial access 
P T H parat h or m o ne 
P V C pre mat ure ve ntric ular c o ntracti o n/c o m ple x 
Q D o nce dail y
Q Tc c orrecte d Q T i nter val 
Q Tc F Q Tc c orrecte d usi n g Fri dericia’s f or m ula 
Q T L qualit y  tolera nce li mit 
q ual q ualitati ve 
R B C re d bl o o d cell 
R N A ri b o n ucleic aci d 
S A D E seri o us a d verse de vice effect 
S A E seri o us a d verse e ve nt 
S A P Statistical Anal y sis Pla n 
S C s u bc uta ne o us 
S C L s u p pl y  c hai n lea d 
Scr ser u m creati ni ne 
Screat ser u m creati ni ne 0 9 0 1 7 7 e 1 9 e 0f 3 af c\ A p pr o v e d\ A p pr o v e d O n: 1 9- J ul- 2 0 2 3 0 1: 5 5 ( G M T) C CI C CI C CI 
C CI 
P F -0 6 9 5 4 5 2 2 
Pr ot oc ol C4 0 0 1 0 0 1 
Fi nal Pr ot oc ol, 1 7 J ul y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol T e m plate ( 1 4 A pril 2 0 2 3) 
Pa ge [ADDRESS_415446] oca n na bi n ol 
T O C ta ble of c o nte nts 
T S H t h y r oi d -sti m ulati n g h or m o ne 
U A C R uri ne al b u mi n /c reati ni ne rati o 
U L N u p per li mit of n or mal 
U S U nite d States 
U S PI U nite d States Prescri bi n g I nf or mati o n 
U TI uri nar y  tract i nfecti o n 
Vss stea d y -state v ol u me of distri b uti o n 
Vz/ F a p pare nt v ol u me of distri b uti o n f or e xtra vasc ular d osi n g 
W B C w hite bl o o d cell 
W O C B P wo ma n / w o me n of c hil d beari n g p ote ntial 0 9 0 1 7 7 e 1 9 e 0f 3 af c\ A p pr o v e d\ A p pr o v e d O n: 1 9- J ul- 2 0 2 3 0 1: 5 5 ( G M T) C CI 
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page [ZIP_CODE]. REFERENCES
1. Orskov C, Holst JJ, Knuhtsen S, et al. Glucagon-like peptides GLP-1 and GLP-2, 
predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology. 1986;119(4):1467-75.
2. Kreymann B, Williams G, Ghatei MA, et al. Glucagon-like peptide-1 7-36: a 
physiological incretin in man. Lancet. 1987;2(8571):1300-4.
3. Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of 
gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273(5):E981-8.
4. Flint A, Raben A, Astrup A, et al. Glucagon-like peptide [ADDRESS_415447]. 1998;101(3):515-20.
5. Federation ID. IDF Diabetes Atlas. Available from: 
https://diabetesatlas.org/atlas/tenth-edition/. Accessed on: 19 Jun.
6. Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care. 
2011;34(6):1249-57.
7. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new 
paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-95.
8. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular 
and microvascular complications of type 2 diabetes ([LOCATION_006]PDS 35): prospective observational study. BMJ. 2000;321(7258):405-12.
9. Nauck MA, Quast DR, Wefers J, et al. GLP-1 receptor agonists in the treatment of 
type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102.
10. Ozempic (semaglutide). US Prescribing Information (USPI). Plainsboro, NJ: Novo 
Nordisk Inc; 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf. Accessed: 16 Jun 2023.
11. Victoza (liraglutide) US Prescribing Information (USPI). Plainsboro, NJ. Novo 
Nordisk Inc; 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022341s027lbl.pdf. Accessed: 16 Jun 2023.
12. Rybelsus (semaglutide) US Prescribing Information (USPI). Plainsboro, NJ. Novo 
Nordisk Inc; 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213051s011lbl.pdf. Accessed: 16 Jun 2023.
13. Victoza (liralutide) USPI. U.S. Food and Drug Administration website. Available 
from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022341s031lbl.pdf. Accessed: 06 Jun 2023.
14. Pratt E, Ma X, Liu R, et al. Orforglipron (LY3502970), a novel, oral non-peptide 
glucagon-like peptide-[ADDRESS_415448]: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes. Diabetes Obes Metab. 2023;10.1111/dom.[ZIP_CODE].
15. Saxena AR, Frias JP, Brown LS, et al. Efficacy and Safety of Oral Small Molecule 
Glucagon-Like Peptide [ADDRESS_415449] Danuglipron for Glycemic Control 090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )
PF-06954522
Protocol C4001001Final Protocol, 17 July 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (14 April 2023)
Page 107Among Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA Netw 
Open. 2023;6(5):e2314493.
16. Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation. 
U.S. Department of Health and Human Services. Food and Drug Administration. July 2009. Available from: https://www.fda.gov/media/116737/download. Accessed on: 28 Jun 2023.
17. Inker LA, Eneanya ND, Coresh J, et al. New Creatinine- and Cystatin C-Based 
Equations to Estimate GFR without Race. N Engl J Med. 2021;385(19):1737-49.090177e19e0f3afc\A pproved\A pproved On: 19-Jul-2023 01:55 (GMT )